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Abstract

Objectives: The purpose of this Doctorate in Nursing Practice (DNP) project was to
improve health outcomes among underserved residents of Nevada county by increasing access to
inter-professional team-based medication assisted therapy (MAT) for opioid use disorder. The
over-arching goal of this DNP project was to develop evidence based, interdisciplinary, nursemanaged MAT services through the initiation of the pilot program for the newly developed MAT
patient delivery system and the development of evidence-based nurse practitioner process
protocols.
Methods: This DNP project involved the coordination of an evidence-based, structured,
nurse-managed MAT group on Wednesdays at Community Recovery Resources (CoRR) Grass
Valley. The group was led by an interdisciplinary team and was attended by patients who were
on a stable dose of an opioid agonist medication. The patients were required to attend the newly
structured Wednesday group to obtain their Suboxone medication refill and any clinical concerns
that the patient had or issues with their current maintenance therapy dose could be addressed by
the provider at that time. Education regarding opioid use disorder, the use of Suboxone in the
treatment of opioid use disorder as well as common side effects of the medication was provided
during the group. The DNP author also assisted with the development of evidence-based nurse
practitioner process protocols for the clinic site.
Results: The retention rate for the patients in the newly developed MAT patient delivery
system exceeded the established benchmark goal of 60%. The initial results of the patient
satisfaction surveys regarding the MAT program were overwhelmingly positive. In addition, to
accommodate the increased number of MAT patients who expressed interest in the new group
format, an additional MAT group day was added on Tuesdays with plans to expand the group
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format to additional CoRR campuses. The results of the provider satisfaction surveys regarding
the MAT program will be added once all results are received.
Conclusion: Medication-assisted treatment (MAT) has proven to be the most effective
evidence-based treatment option for patients with opioid dependence combined with
psychosocial treatment. Treatment of opioid misuse disorder with buprenorphine and naloxone
and/or buprenorphine has been proven to be safe and an effective treatment option in the officebased setting to decrease opioid use and cravings. Due to the new and evolving nature of the
field of substance abuse and medication assisted treatment, it would be beneficial to obtain
further research regarding best practices for providing MAT services to underserved nonmetropolitan communities.
Keywords: medication-assisted treatment, opioids, substance use disorder, drug abuse,
heroin, overdose deaths, opioid addiction, buprenorphine, opioid related disorders, rural,
primary health care, mortality, and safety net.
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Section I: Introduction
Background Knowledge
The American Society of Addiction Medicine (2016) characterizes addiction as a
“primary, chronic and relapsing brain disease characterized by an individual pathologically
pursuing reward and/or relief by substance use and other behaviors.” Opioids are a class of drugs
that communicates with opioid receptors on nerve cells in the brain and the nervous system
which results in feelings of pleasure and pain relief (American Society of Addiction Medicine,
2016). This category of drugs includes prescription pain relievers such as oxycodone,
hydrocodone, codeine, morphine and fentanyl and the illicit drug heroin. The Centers for Disease
Control and Prevention (2017) reported that 42,000 Americans died from Opiates in 2016 which
surpassed any other year on record. This number includes death from prescription opioids, heroin
and fentanyl (Centers for Disease Control and Prevention, 2017). According to the California
Healthcare Foundation (2016), California ranks 37th for prescription opioid deaths although rural
northern California counties had some of the highest overdose death rates in the country and
limited access to addiction treatment. The development of Medication Assisted Therapy
Services, frequently referred to as MAT services, was initiated in response to the significant
increase in heroin and opioid-related overdoses in the United States and the adverse health
outcomes associated with opioid addiction (SAMHSA-HRSA Center for Integrated Health
Solutions, 2014). According to the SAMHSA-HRSA Center for Integrated Health Solutions
(2014), there is increased access to MAT services in many states through the development and
reform of Medicaid for those with substance use disorders, although, many do not receive these
services do to underutilization or restricted access to these programs. The data indicates a
significant need for nurse-managed community-based MAT services, especially in non-
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metropolitan Northern California counties, where opioid overdose rates remain high and access
to services limited. Community Recovery Resources (CoRR) Grass Valley is a non-profit
organization located in the Sierra Nevada foothills serving those with drug and alcohol addiction
and related mental health disorders making it an ideal location for the implementation of nursemanaged community-based MAT services, especially since its location is in a high risk nonmetropolitan Northern California county (Community Recovery Resources, 2018).
Problem Description
The opioid epidemic in America traces its roots back to the Civil War where opioids
we’re being prescribed for pain, various illnesses and stress (Center for Substance Abuse
Treatment, 2005). As the years passed the demographics of those addicted to opioids shifted to
middle- and upper-class white women who were prescribed these medications for “female
troubles” and Civil War veterans who were given opioids for medical procedures (Center for
Substance Abuse Treatment, 2005). Although, physicians became less inclined to prescribe
opioids by the close of the 19th century, and in turn, the amount of Americans addicted to
opioids declined. In addition, social attitudes toward opioid addiction shifted from that of
compassion and empathy to a society that viewed it as unethical and something that was frowned
upon (Center for Substance Abuse Treatment, 2005).
The opioid epidemic continues to be a significant medical and social issue in the United
States today with the amount of overdoses due to opioids rising. The Centers for Disease Control
and Prevention (2017) reported that 42,000 Americans died from Opioids in 2016 which
surpassed any other year on record. This number includes death from prescription opioids, heroin
and fentanyl (Centers for Disease Control and Prevention, 2017). Alarmingly, in the United
States, drug overdoses are the leading cause of injury death and the rate of drug overdose deaths
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is increasing in non-metropolitan areas compared to urban areas (Centers for Disease Control,
2018). Mack, Jones and Ballesteros (2017) found in their report that the prevalence of drug use
in non-metropolitan areas was lower than that of their urban counterparts but the ramifications of
drug use in rural areas was increased (i.e. diagnosed with Hepatitis C virus or HIV). In addition,
the authors stated that availability and access to substance abuse treatment services was less
prevalent in non-metropolitan communities (Mack, Jones, & Ballesteros, 2017). Noonan (2017)
details the disparities that non-metropolitan communities face such as socio-economic factors,
health practices and access to health care services which makes these communities vulnerable to
the opioid epidemic.
Although the total opioid related death rates in California are lower than the numbers in
other states, there remains specific counties in California that have some of the highest opioid
prescribing rates and death rates in the United States (Joshi & Urada, 2017). Rural Northern
California counties have the leading number of opioid prescriptions per 1,000 residents and
prescription opioid related deaths per resident is also highest in these same counties (Joshi &
Urada, 2017). Furthermore, Joshi and Urada (2017) state that while Nevada, El Dorado, Colusa,
Mendocino, Del Norte and Humboldt counties have some of the highest overdose death rates,
fewer than 10 patients were enrolled in opioid treatment programs in 2016. In addition, in 2016,
the top eight counties in Northern and Central Eastern California with the highest number of
opioid overdoses did not have Narcotic Treatment Programs (NTP) (Joshi & Urada, 2017). The
data highlights a significant need for treatment options for this patient population specifically in
non-metropolitan Northern California counties who remain the hardest hit by the opioid
epidemic in California.
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In response to the opioid epidemic in California, the state developed a California Hub and
Spoke System (H&SS) included in the MAT Expansion Opioid State Targeted Response (STR)
grant program which is based on the Vermont Hub and Spoke Model (Darfler et al., 2018). The
Vermont Hub and Spoke Model is based on developing a structured specialty and referral
network for both higher levels of care and office-based treatment environments (Darfler et al.,
2018). The California Hub and Spoke MAT Expansion Program was created to “improve,
expand, and increase access to MAT services throughout the state, especially in counties with the
highest overdose rates” (Darfler et al., 2018). The goal of this program is to increase the number
of providers (i.e. physicians, nurse practitioners, physician assistants) who are prescribing
buprenorphine for opioid misuse disorder which in turn would make MAT more accessible for
this patient population in the highest risk regions of the state (Darfler et al., 2018).
MAT in conjunction with psychosocial treatment has been shown to be the most effective
evidenced based treatment option for this patient population (Jones, 2018). There are several
medication options for MAT, but this paper and DNP project focused on Buprenorphine.
Buprenorphine is an opioid agonist/antagonist that obstructs the effects of other narcotics while
at the same time reducing the withdrawal risk and has several different formulation options
(Center for Substance Abuse Treatment, 2016). An advantage of Buprenorphine in comparison
to Methadone treatment for opioid dependency is that Buprenorphine is the first medication that
is authorized to be prescribed and given in a healthcare provider’s office instead of a highly
structured clinic increasing patient access to treatment (Center for Substance Abuse Treatment,
2016). Although, the use of this medication is not intended to be in isolation and is most
effective in combination with counseling and behavioral therapy representing a comprehensive
“whole-patient approach” (Center for Substance Abuse Treatment, 2016). Physicians are
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mandated to attend an 8-hour training session to be granted a Drug Enforcement Agency (DEA)
waiver to have prescribing ability of Buprenorphine and prescribing ability for other health care
providers is broadening (Jones, 2018).
The location of Community Recovery Resources (CoRR) Grass Valley in a nonmetropolitan Northern California county made it an ideal location to serve a community at high
risk for prescription and illicit opioid dependence and opioid related death. As previously
discussed, the research indicates that non-metropolitan communities have high rates of
prescription and illicit opioid use and related deaths and decreased access to medication assisted
therapy. In addition, according to the Community Recovery Resources (CoRR) Chief Executive
Officer (CEO), approximately 75% of people receiving services at CoRR are low income
(Curtis, 2018). This presented an opportunity to better serve this high-risk community through
the development and implementation of a nurse managed community-based medication assisted
therapy services, through the support of the California H&SS grant, to address and combat the
effects of the opioid epidemic in this area and support continued sobriety and health and wellbeing in this patient population.
Specific Aims
The over-arching aim of this DNP project was to improve health outcomes among
underserved residents of Nevada county by increasing access to inter-professional team-based
MAT for opioid use disorder through the development of evidence based, interdisciplinary,
nurse-managed MAT services through the initiation of the pilot program for the newly developed
MAT patient delivery system and the development of evidence-based nurse practitioner process
protocols. An aim statement was created to address the proposed programs intended
improvement to practice and is as follows, by March 2019, Community Recovery Resources
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(CoRR) Grass Valley Campus will develop and implement nurse-managed community-based
medication assisted treatment services in Nevada county to improve access and health outcomes
for those with opioid use disorder with a retention rate benchmark goal of 60% for patients in the
program. In addition, based on the success of this DNP project, an aim is to expand the nurse
managed-community based medication assisted treatment services to be offered on additional
days at the CoRR Grass Valley campus as well as to additional campus locations.
PICOT
The PICOT question developed for the aforementioned DNP project is as follows: In
patients with opioid use disorder in an underserved non-metropolitan Northern California
community, will increasing access to interprofessional team-based MAT for opioid use disorder
improve health outcomes?
Search Process
A review of the literature was conducted to examine the lack of access to MAT for
underserved residents in non-metropolitan communities with opioid misuse disorder. In addition,
a literature search was conducted to determine the current demographic landscape of illicit and
prescription opioid dependent users and the economic impact of prescription opioid overdoses,
abuse and dependence. Although there are several options for maintenance therapy for opioid
dependence, the focus of this DNP project and research was specifically on office-based use of
buprenorphine-naloxone. Lastly, the research conducted also evaluates the decreased risk of
other comorbidities, such as Hepatitis C, in opioid dependent patients who receive opioid agonist
therapy. The key words used in the search process were: medication-assisted treatment, opioids,
substance use disorder, drug abuse, heroin, overdose deaths, opioid addiction, buprenorphine,
opioid related disorders, rural, primary health care, mortality, and safety net. The databases
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utilized in the search were the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PubMed, Google Scholar and Cochrane. The search was conducted in SeptemberNovember of 2018 and generated 107 articles. The inclusion criteria for articles that were
selected were articles published between the years of 2001-2018, those written in English, those
examining illicit and prescription opioid use, medication assisted therapy for opioid
abuse/dependence, demographic characteristics of opioid misuse and the economic impact of
opioid overdose, abuse and dependence. The exclusion criteria included articles not written in
English and those published before 2001.
Evidence Appraisal Tool
The research articles selected for this DNP project were appraised utilizing the John
Hopkins Evidence-Based Practice (JHNEBP) Research Evidence Appraisal Tool (Appendix R).
This rating scale examines the strength of the evidence (i.e. Level I-V) and the quality of the
evidence (i.e. A-C).
Review of the Evidence
The opioid epidemic remains at the forefront as a significant medical and social issue in
the United States today. Although California as a state has lower opioid related death rates when
compared to the numbers in other states, specific counties in California continue to have some of
the highest opioid prescribing rates and death rates in the United States (Joshi & Urada, 2017).
As previously mentioned, Joshi and Urada (2017) further state that specifically counties in rural
Northern California counties have some of the highest prescription opioid prescribing rates and
prescription opioid related death rates in the country. Cicero et al. (2014) describes the
demographic shift in Heroin users, many previously prescription opioid dependent, from
minority inner city users to Caucasian men and women living in non-metropolitan areas.
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Although the data has demonstrated a significant amount of opioid misuse and dependence in
non-metropolitan areas, Rosenblatt et al. (2015) report that only 3% of primary care providers
had received the Drug Enforcement Administration (DEA) DATA waivers which represents the
biggest group of providers in non-metropolitan areas in the U.S, indicating a lack of access to
office-based treatment for opioid disorders in rural areas. In addition, Jones (2018) state that
health care centers located in non-metropolitan areas were less likely to provide on-site
buprenorphine treatment.
Jones (2018) reports that the most effective evidence-based treatment option for patients
with opioid dependence is MAT in conjunction with psychosocial treatment. Furthermore,
research conducted by Renner et al. (2003) concluded that treatment with combination
buprenorphine and naloxone and buprenorphine were safe for use and a reduction in the use of
opiates and cravings were seen for patients that were opiate dependent and receiving these opioid
agonist medications in the office-based setting. In addition, a study conducted by Tsui et al.
(2014) found that the use of opioid agonist therapy, either methadone or buprenorphine, may
help to prevent the contraction of hepatitis c infection in this patient population. Increased access
to opioid agonist treatment (i.e. methadone or buprenorphine) can also be correlated with a
reduction in the number of heroin overdose deaths (Schwartz, 2013).
Theoretical Framework
Treatment of the opioid dependent patient is multi-faceted and dynamic and applying an
ecological model for health promotion in this patient population addresses both individual and
social environmental factors allowing for more comprehensive interventions and treatment
modalities (McLeroy, Bibeau, Steckler & Glanz, 1988).
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The ecological perspective is centered on the idea that behavior is affected by “multiple
levels of influence” and that an individual’s behavior both affects and is affected by the social
environment (U.S. Department of Health and Human Services, National Cancer Institute, 2005).
This framework focuses on the interaction of and the interconnection between the different levels
of influence of a health problem (U.S. Department of Health and Human Services, National
Cancer Institute, 2005). McLeroy, Bibeau, Steckler and Glanz (1988) define five levels of
influence when looking at health related behaviors and conditions which consist of 1)
intrapersonal or individual factors; 2) interpersonal factors; 3) institutional or organizational
factors; 4) community factors; and 5) public policy factors (U.S. Department of Health and
Human Services, National Cancer Institute, 2005). Through targeted interventions at all levels of
influence a patient’s unhealthy behavior(s) can be changed and modifying the social environment
can lead to behavior changes in the individual as well (McLeroy, Bibeau, Steckler & Glanz,
1988).
Providers can target interventions at the intrapersonal level by focusing on the patient’s
distinct characteristics that impact their behavior (U.S. Department of Health and Human
Services, National Cancer Institute, 2005). Interventions at the intrapersonal level for the opioid
dependent patient would include screening measures to prevent further adverse outcomes and
educational programs directed at opioid misuse. Based upon findings of screening measures
employed, the provider can institute interventions to treat the opioid dependency such as MAT,
counseling, support groups etc. Interventions at the inter-personal level would consist of peer
support groups (i.e. Narcotics Anonymous, MAT groups), family support groups, group therapy
and residential or transitional living support groups. The community level of influence includes
institutional and community factors as well as public policy (U.S. Department of Health and
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Human Services, National Cancer Institute, 2005). Efforts at the institutional level, when
examining opioid dependence, focus on adhering to trusted guidelines for prescribing opioids
(Centers for Disease Control and Prevention, 2017) and abiding by state prescription drug
monitoring policies (i.e. Cures). Examples of community factors would include social media
opioid misuse awareness campaigns and the distribution of Narcan kits to the community. Lastly,
an example of interventions directed at the public policy level would include legislation focused
on increasing access to medication-assisted therapy for opioid dependent patients in high risk
non-metropolitan communities.
This DNP project employed the ecological framework when examining the opioid
epidemic and in the development of interventions for the patient with opioid use disorder as this
perspective applies a multilevel approach to a health problem and incorporates the role of the
social environment. Utilizing the ecological framework as a guide for the DNP project
intervention allowed for the provision of comprehensive, interdisciplinary care for the patient
with opioid use disorder.
Section II: Methods
Setting
The DNP project implementation site is CoRR in Grass Valley and it is a non-profit
organization that has been serving the community since 1974 through substance abuse treatment
programs and providing mental health services since 2002 (Community Recovery Resources,
2018). CoRR Grass Valley is located in the Sierra Nevada foothills and offers extensive
substance abuse treatment and primary care treatment. The mission of CoRR is to “support the
communities [they] serve with a full spectrum of wellness-focused programs to reduce the social,
health and economic impact on families and children from all types of substance abuse and
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behavioral health issues” (Community Recovery Resources, 2018). The organization focuses on
a “whole-person approach in treating substance abuse, related addictions and associated
behavioral issues” and has five other campuses in the region (Community Recovery Resources,
2018).
The clinic serves a non-metropolitan high risk opioid dependent population that are either
being treated as an outpatient, in residential treatment or are in transitional living. Nevada county
is a non-metropolitan county that is located between Sacramento and Tahoe. It has a population
of approximately 99, 814 and is predominantly Caucasian (85.2%) (U.S. Census Bureau, 2017).
The median household income is $57,429 which falls below the median income for California
($63,783) (U.S. Census Bureau, 2017). CoRR has been identified as the primary nonprofit
provider of substance use disorder and related behavioral services for Nevada and Placer
counties in California. In Nevada county it is estimated that there are 230-594 patient with opioid
use disorder that do not have local access to MAT (Clemens-Cope, Epstein, & Wissoker, 2018).
Furthermore, in Placer county it is estimated that 686-2,149 patients with opioid use disorder
who do not have local access to MAT (Clemens-Cope, Epstein, & Wissoker, 2018).
The treatment team consists of a physician, nurse practitioner, physician assistant,
program coordinator and two medical assistants. CoRR Grass Valley received a California Hub
and Spoke (H&SS) System Grant to improve and expand access to medication-assisted therapy
for opioid dependent patients (Appendix D, E). The clinic was in the initial stages of utilizing the
grant funds for medication-assisted treatment and did not have approved process protocols,
updated prescribing policies for buprenorphine and naltrexone or updated MAT treatment forms
at the initiation of the DNP project.
Context

THE DEVELOPMENT AND IMPLEMENTATION OF

18

The DNP project was implemented in a community-based setting at a substance use
recovery clinic in a non-metropolitan county in northern California. The identified patient
population were underserved residents of a non-metropolitan community who had opioid use
disorder.
Prior to the implementation of the project, the DNP student collaborated with the Medical
Director, Nurse Practitioner, Physician’s Assistant, Clinical Coordinator and the Substance Abuse
Counselor to develop a nurse managed, interdisciplinary, evidence-based structured clinical
schedule, protocol and workflow for the MAT group patients on Wednesdays (Appendix K, M)
and discuss the logistics of the project. There were 47 patients with opioid use disorder, who were
on a stable maintenance dose of Suboxone, who participated in the MAT Wednesday pilot
program. The MAT Wednesday group was led by the Substance Abuse Counselor, in collaboration
with the Medical Director, Nurse Practitioner, Clinical Coordinator DNP student and Medical
Assistant for approximately one hours in conference room #104 at the CoRR Grass Valley campus.
The Medical Director, Nurse Practitioner and DNP student were available to answer any questions
the patients may have during the group and to see patients after group who had a clinical concern
or needed an adjustment of their maintenance Suboxone dose. A comprehensive description of the
interventions of this DNP project can be found in the interventions section of this paper.
Key Stakeholders
The primary stakeholders of this DNP project were the patients and families served and
the Nevada and Placer communities. Feedback from the primary stakeholders regarding the
newly developed MAT group was received through the use of anonymous patient satisfaction
surveys administered in February 2019 and again in April 2019 for continuous evaluation of the
strengths and weaknesses of the program. The organizational stakeholders were Ariel King
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Lovett (Chief Executive Officer), Dr. Scott Kellerman (Medical Director, project oversight), Dr.
Alexa Curtis, PhD, MPH, FNP-BC (project coordinator), Michelle Otten (Clinical Coordinator),
and Lauren Knapp, DNP student intern as the project manager. The organizational stakeholders
were involved in the development and revision of the MAT group pilot program through
interdisciplinary weekly meetings prior to the start of the group and through email. The
implementation of nurse managed community-based medication assisted treatment services for
an underserved non-metropolitan northern California community at CoRR Grass Valley was
sanctioned by the CoRR Medical Director, Dr. Scott Kellerman, the CoRR Nurse Practitioner,
Dr. Alexa Curtis, and the CoRR Clinical Coordinator Michelle Otten. The aforementioned
project proposal was approved by committee chair Dr. Alexa Curtis. A written letter of support
from Community Recovery Resources (CoRR) is included (Appendix B). Lastly, prior to the
implementation of the DNP project a memorandum of agreement (MOU) was signed between
the University of San Francisco (USF) and the project site, Community Recovery Resources
(CoRR) in Grass Valley.
Communication Flow
The fluid communication flow between all members of the interdisciplinary team was
imperative for the success of the DNP project. The DNP student was in direct communication
with the Committee Chair and members of the collaborative treatment team at CoRR Grass
Valley throughout all stages of the project. Any revisions to the format of the MAT group,
updated clinical documentation or change in the process or protocols was communicated to all
members of the team. A detailed communication plan was created for the DNP project
(Appendix H).
GANTT Chart
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A GANTT chart was created to organize each step of the DNP project and highlight the
projected milestones (see Appendix J). Prior to the initiation of the project, a literature review
was conducted regarding opioid dependence and medication assisted therapy for opioid
dependence. After the DNP clinical improvement project topic was approved, the DNP student
then created a project team. Meetings with the DNP student and the stakeholders and members of
the health care team at the project implementation site were conducted. The DNP student, in
collaboration with the Clinical Coordinator and Substance Abuse Counselor, identified patients
to be enrolled in the structured MAT Wednesday clinic groups. The development of MAT group
policies and workflows, updated prescribing policies, process protocols and patient and provider
resources were developed at this time. The DNP project implementation occurred over a fourmonth period beginning in January to April 2019 after which data was collected analyzed. A
Patient satisfaction survey was disseminated in February of 2019, one month after the initiation
of the project implementation, and again in April of 2019 to receive feedback from the MAT
patients regarding the program and to allow for any revisions to be made to the format of the
group. A provider satisfaction survey was also conducted in the month of April 2019. Lastly, the
final DNP written project began in April 2019 and the presentation of the project and results
were presented to the USF faculty in May 2019.
Gap Analysis
The purpose of a gap analysis is to improve processes through examining the current state
of the issue being addressed, determine the future goal of where one would like that state to be,
and create a plan of how to achieve that desired state. A gap analysis was conducted for the
proposed DNP project (Appendix I). A study conducted by Jones (2018) found that health
centers in non-metropolitan areas were less likely to provide on-site buprenorphine treatment and
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had decreased odds of having an interest in expanding services to provide buprenorphine
treatment. Furthermore, research conducted by Rosenblatt, Andrilla, Catlin, and Larson (2015)
concluded that most counties in the United States did not have access to waivered physicians to
prescribe buprenorphine-naloxone and suggested increasing access to office-based opioid
dependence treatment especially in rural areas where access to such services was limited.
Currently, as evidenced by the data, there is limited access to MAT services in non-metropolitan
areas where opioid prescription rates and prescription opioid related deaths remain high. It is
essential that in the future there is increased access to community-based medication assisted
therapy for opioid dependence for this high-risk population to counteract the ravaging effects of
the opioid epidemic on high risk communities. Community Recovery Resources located in Grass
Valley is located in Nevada county, a non-metropolitan community in Northern California that
has a high risk opioid dependent population making it an ideal site for practice improvement.
SWOT Analysis
A SWOT analysis was conducted to identify the strengths, weaknesses, opportunities and
threats that could affect the implementation of the nurse-managed community-based medication
assisted treatment services for the underserved community of Nevada county (see Appendix C).
A valuable strength of this project is that it addressed the issue of inadequate access to MAT
services for opioid dependent patients in non-metropolitan areas, especially in rural Northern
California counties where opioid prescription rates and opioid related death rates are highest.
Additional strengths of this project were the potential impact it could have on the rate of
prescription opioid related deaths and decreased rates of transmission of communicable diseases
such as Hepatitis C. Furthermore, the DNP project could result in a potential cost savings
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through the decreased utilization of inpatient detoxification services and the increased
distribution of Narcan kits to the community and high-risk groups.
A weakness of the project is the lack of waivered prescribers to meet the treatment needs
of the MAT patients. In addition, other weaknesses are the lack of patient transportation to CoRR
Grass Valley for treatment and patient demographics such as unstable housing, geographical
distance from the clinic and lack of support system. Lastly, other weaknesses are patients not
being covered by the H&S grant and those who are unable to pay for treatment and patient
adherence to Suboxone induction/maintenance therapy.
The DNP project offers an invaluable opportunity to serve the community of Nevada
county and those patients that belong to vulnerable, high risk groups. This project provides the
opportunity to increase access to MAT services to this non-metropolitan community and reduce
the number of illicit and prescription related deaths. There is also an opportunity for continued
H&S grant funding for the MAT program at CoRR. An additional opportunity that this project
presents is to reduce the transmission of communicable diseases in this high-risk population
through the use of opioid agonist medication adherence and education. Lastly, there is an
opportunity to provide education to patients, families and the community regarding the use of
Narcan and its lifesaving properties and also dispense physical Narcan kits.
The SWOT analysis conducted identified the following potential threats to the project:
loss of H&SS funding, opioid dependent patients in need of MAT services unable to access
treatment, pharmacies out of stock of opioid agonist medication, patients leave MAT treatment,
no change in the rate of illicit and prescription opioid related deaths and a loss of waivered
prescribers.
Budget
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The medication-assisted treatment services at CoRR Grass Valley is funded through the
California Hub and Spoke (H&SS) Grant (Appendix D, E). The clinic is directly reimbursed for
the salary and benefits of one FTE Nurse and one FTE Clinician/Counselor per 100 H&S
patients (i.e. 0-20 patients = 8 hrs. paid per week, 20-40= 16 hrs. paid per week, etc.). For
Physicians and Mid-Level waivered providers the H&S grant reimburses $180 for Suboxone
induction office visits for uninsured and underinsured patients and $100 for Suboxone follow-up
visits. The grant also reimburses for patient transportation, physician and mid-level time in
training and MAT training materials. The Clinical Coordinator submits a monthly invoice form
to Aegis for reimbursement, whom the H&S grant is funded through, and reports the monthly
personnel costs (i.e. MAT Nurse, MAT clinician), Provider H&S induction and follow-up,
treatment services (drug testing, human immunodeficiency virus (HIV) and Hep-C testing,
Suboxone/Naloxone/Vivitrol costs, miscellaneous services (i.e. bus passes, gas/fuel cards,
trainings, infrastructure) and outreach and advertising expenses (Appendix D, E).
The clinic personnel, providers, treatment services and miscellaneous services are
reimbursed through the H&SS Grant and were therefore not included in the DNP project budget.
A budget for the development and implementation of this DNP project was created and included
direct and indirect costs (Appendix F). Direct costs incurred for the project were for materials,
coffee and donuts on the first day of the MAT Wednesday group and NP travel costs (i.e.
mileage/gas). The cost of materials totaled $65.78 and included patient satisfaction surveys,
handouts, and writing utensils to fill out the surveys. On the first day of the MAT Wednesday
pilot program coffee and donuts were provided for the patients that attended as well as the
interdisciplinary team and the cost totaled $50. Lastly, the DNP student traveled by car to the
clinic site in Grass Valley which is approximately 98 miles a week, for at least two Wednesdays
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a month, for four months totaling $240 in fuel cost. The total cost of direct expenses was
approximately $356 paid out-of-pocket by the DNP student. The indirect expenses accounted for
the DNP student’s time and project management and implementation and totaled $3,904. The
total budget, including both direct and indirect expenses was $4,260.
Florence, Luo, Xu and Zhou (2016) report that prescription opioids are responsible for
70% of fatal prescription drug overdoses and the number of overdose deaths due to prescription
drugs is considered to be an epidemic. It is imperative that the economic impact of prescription
opioid overdose, abuse and dependence in the United States be understood as this data will
influence future clinical practice in treating this patient population, future research and
legislation (Florence, Luo, Xu and Zhou, 2016). Florence, Luo, Xu and Zhou (2016) examined
the societal costs of prescription opioid abuse, dependence and fatal overdose in the United
States based on the most up to date applicable data for the calendar year 2013 (Appendix F). The
authors further differentiated between nonfatal costs such as health care, substance abuse
treatment, criminal justice and lost productivity and fatal costs defined as lost productivity and
health care (Appendix F) (Florence, Luo, Xu and Zhou, 2016). Florence, Luo, Xu and Zhou
(2016) estimate that the total economic cost of prescription opioid overdose, abuse and
dependence is $78.5 billion. Furthermore, they report that $28.9 billion is spent on increased
health care costs and substance abuse treatment expenses which accounts for over one third of
the total economic cost (Florence, Luo, Xu and Zhou, 2016). Lastly, the authors report that the
public sector absorbs roughly one quarter of the estimated total economic cost through
expenditures related to health care, substance abuse treatment and criminal justice (Florence,
Luo, Xu and Zhou, 2016).
When examining the cost benefit of this project, the total nonfatal cost of prescription
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opioid misuse in the United States in 2015 was examined based on data from Florence et al.
(2016) (Council of Economic Advisors, 2017). The nonfatal costs include increased healthcare
and substance abuse treatment costs ($29.4 billion), increased criminal justice costs ($7.8 billion)
and reduced productivity among those who did not die of overdose ($20.8 billion) (Council of
Economic Advisors, 2017). It is to be noted that this data includes the average cost estimates for
prescription opioid disorders only (Council of Economic Advisors, 2017). The estimated cost to
implement the DNP project for a full year was $12,779. The benefit of implementing the DNP
project over the course of year would be increased access to evidence based, interdisciplinary
MAT services for high-risk, underserved patients with opioid use disorder in non-metropolitan
communities and in turn decrease the increased healthcare costs, criminal justice costs and
decreased productivity associated with the diagnosis. The calculated cost benefit ratio of the
DNP project was 2.35 which indicates that it is “economically satisfactory” (Tayari, 2018).
Interventions
Developmental Phase: During the initial phase of this project research was conducted on
the opioid epidemic in the United States, the current demographics of this epidemic, the
economic burden of opioid dependency, abuse and overdose and best practices for medicationassisted therapy for opioid dependence and the California Hub & Spoke Grant for MAT services
to address the epidemic. The project manager then proposed the clinical improvement project to
the Medical Director, Nurse Practitioner, Physician’s Assistant and Clinical Coordinator at
CoRR Grass Valley. During this phase the project manager sought educational opportunities to
become more knowledgeable about medication-assisted treatment for opioid addiction in opioid
treatment programs through reading the Substance Abuse and Mental Health Services
Administration (SAMHSA) “Treatment Improvement Protocol TIP 43”, discussing opioid
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dependency and MAT practices with CoRR providers and local experts (i.e. Grace Katie Bell,
MSN, RN-BC CARN PHN at Chapa De Indian Health), shadowing an experienced MAT
provider at El Dorado Community Health Center and reviewing California’s Hub and Spoke
System Learning Collaborative power point. The project manager also participated in
Wednesday morning staff meetings with the Medical Director, Nurse Practitioner, Physician’s
Assistant and Clinical Coordinator discussing the development of the MAT program at CoRR,
complex patient cases and any current clinical issues.
During this phase, the DNP student met with the Clinical Coordinator and Substance
Abuse Counselor to determine which patients would be appropriate to participate in Wednesday
MAT group classes with the interdisciplinary team, at which time, Suboxone medication refills
for maintenance therapy would be dispensed and any patient clinical concerns or medication
dosing concerns would be addressed. The DNP student met with her Committee Chair, Dr. Alexa
Curtis, and presented the DNP project proposal which was approved for implementation. A
memorandum of agreement (MOU) was obtained between the University of San Francisco and
the project implementation site, CoRR Grass Valley prior to implementation.
Educational and Delivery of Interventions into Practice Phase: The DNP student led
the coordination of the MAT Wednesday group classes with the interdisciplinary team including
securing the conference room for the group, communicating with all members of the team,
assisting in notifying patients of acceptance into MAT Wednesday group class and opioid
agonist medication refill schedule (i.e. attendance at Wednesday class mandatory for medication
refill, any clinical concerns can be addressed at Wednesday group class) (Appendix K).
The Wednesday MAT group class was held by Steve Black, Substance Abuse Counselor
at CoRR Grass Valley, and all MAT providers were present during the MAT group. The
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interdisciplinary team of MAT providers present at the group included the Medical Director,
Nurse Practitioner, Clinical Coordinator, DNP student and Medical Assistant(s). The structure of
the Wednesday MAT group to include the interdisciplinary team, and behavioral health therapies
in conjunction with pharmaceutical management is aligned with best practice for the treatment of
opioid use disorder (American Association of Addiction Medicine (ASAM), 2015). Prior to the
start of the MAT group, each patient was expected to provide a urine sample for urine drug
screen, in concordance with their contract for being on opioid agonist therapy (i.e. Suboxone),
and they were to fill out the first page of the Suboxone maintenance therapy progress note
(Appendix L). The progress note allowed the patient to communicate with the MAT provider
their current maintenance dose of Suboxone, their refill schedule and preferred form of the
medication (i.e. SL strips or tablets), how they were doing on their current maintenance dose, if
they had used alcohol in the past week and if they had any clinical concerns or needed to be seen
by a provider after the group.
The topics covered during the one-hour MAT group were based on subject matter
developed by Kaiser Permanente for the standard medical management of opioid dependence
with Suboxone in a group setting (Kaiser Permanente, 2015). There was on average, 12 patients
present for each MAT group and each patient would do a “weekly check-in” at the start of each
group. Each patient would introduce themselves to the group, state how many “sober days” they
had thus far, discuss cravings experienced in the last week, benefits/side effects of
buprenorphine/naloxone, what self-help meetings they had attended that week and any emotional
or physical pain experienced and the coping skills they had utilized. Patients also were able to
ask the MAT providers questions regarding Suboxone, side effects they were experiencing or
any other clinical concerns in real time during the group and also had the opportunity to meet
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with the MAT provider after the group in the clinic to have their concerns addressed. The DNP
student, in collaboration with the Medical Director and Nurse Practitioner, also helped to screen
and diagnose opioid use disorder for newly admitted patients and provided MAT services to new
and established patients at CoRR.
During this phase, the DNP student assisted in the development of new updated
prescribing policies procedures (Appendix M) and a specific maintenance therapy progress note
for the MAT group (Appendix K). The updated prescribing policies are awaiting final approval
by the Medical Director at the time that this paper was written. In addition, modifications were
made to the Wednesday MAT group structure and associated documentation based on patient
and provider feedback throughout the course of the program. After the initial MAT groups in
January, a need was identified for an updated MAT progress note for the groups as some of the
documentation was not pertinent for patients attending the group or could not be obtained due to
the nature of the group setting as well as other documentation that was needed that was not on
the initial form. Due to the positive feedback and interest after the initial MAT Wednesday
groups in January, the program was expanded to include an additional MAT group on Tuesdays.
A patient satisfaction survey was disseminated in March, two months after the start of the DNP
project, to collect patient feedback on the newly implemented program (Appendix N) and allow
for any changes to be made. The DNP project implementation occurred over a four-month period
although, was extended into practice after the established completion date due to the success of
the program with plans to expand to other CoRR locations.
The interventions of this DNP project were guided by the ecological framework as opioid
use disorder is multi-dimensional and the different levels of this perspective allow for
comprehensive and collaborative treatment for patients with this disorder. The intrapersonal and
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interpersonal levels of the ecological framework were addressed through the interventions
through the MAT services provided to the patients and families. The institutional and
organizational levels of the framework were fulfilled through the creation of updated policies,
procedures and process protocols as well as updated MAT group maintenance therapy progress
notes. Lastly, the community aspect of the ecological framework was addressed through the
DNP student meeting with community experts on opioid use disorder and stakeholders.
Method of Evaluation
During the educational and delivery phase of the project, a paper patient satisfaction
survey was administered two months after the project implementation and at project completion
to obtain quantitative data regarding MAT services utilizing a Likert scale. In addition,
descriptive statistics were obtained in regard to patient age, gender and poverty level. Qualitative
data was obtained through a narrative portion of the patient satisfaction survey and also through
individual interviews with MAT patients and providers. A provider satisfaction survey was
obtained online through Survey Monkey at the completion of the project to gain feedback about
the project. Lastly, retention in recovery will be analyzed through the use of MAT group
attendance data and will be evaluated against the benchmark of 60% based on the literature
(Lagisetty, Klasa, Bush, Heisler, Chopra, Bohnert, 2018).
The objectives of the DNP project were:
1.

Increase access to nurse managed, inter-professional, team-based medication assisted
therapy (MAT) for opioid use disorder through the attendance of at least 10 patients
at the first Wednesday MAT group on January 2nd, 2019.
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2. The creation of updated policies, procedures and process protocols based on
evidence-based practice for Nurse Practitioners at CoRR, in collaboration with the
other MAT team members, by April 24th, 2019.
3. Measure the success of the newly developed MAT group delivery system in meeting
the needs of the patient with opioid use disorder through the calculation of the
retention in recovery rate and compare that against the benchmark of 60% in the
literature by April 25th, 2019.
Patient Satisfaction Survey. A paper patient satisfaction survey regarding the MAT
Group program on Tuesdays and Wednesdays was given two months after the start of the
program in March 2019, and at the project completion in April 2019 (Appendix N). The patient
satisfaction survey questions were appropriated from a patient satisfaction survey created by Lee,
Arria, Hsu and Wish (2003) for a pilot study that they conducted regarding patient satisfaction
with drug treatment in Maryland. The survey was anonymous and consisted of five questions
with the last question allowing for a narrative response from the patient. The responses from the
two groups of MAT patients were examined and an excel bar graph was created based on the
responses from questions one through four. Patterns were identified from the patient responses to
the last narrative question on the survey.
Provider Satisfaction Survey. An electronic, anonymous, provider satisfaction survey
regarding the MAT Group program was created using Survey monkey and sent to the Medical
Director, Nurse Practitioner and Clinical Coordinator at the completion of the DNP project.
There were four questions created by the DNP student. The first three questions addressed what
qualities or characteristics the provider felt made a successful MAT program, what qualities or
characteristics they felt made a successful MAT program at CoRR and what they would like to
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see changed or improved upon. The last question asked if they would like to see the Tuesday and
Wednesday MAT Group continue at CoRR and allowed for a yes or no answer or “other” with a
space provided for comments.
Analysis
The quantitative data obtained from the patient satisfaction surveys regarding satisfaction
with MAT Group services, utilizing a Likert scale, was entered into an Excel spreadsheet and a
bar graph was generated displaying the results of the survey. Descriptive statistics were collected
regarding patient age, gender and poverty level/funding status and were displayed in a table.
MAT Group attendance data was entered into an Excel spreadsheet, including demographic data
such as gender and age range, and the retention rate in recovery was calculated into a percentage
to compare with the benchmark of 60% established in the literature. A provider satisfaction
survey was administered electronically, which yielded narrative responses to questions and was
included in a table.
Ethical Considerations
The proposed DNP project was approved by the University of San Francisco School of
Nursing and Health Professions as a quality improvement project exempt from institutional
review board (IRB) (Appendix A). In addition, a memorandum of understand (MOU) was signed
between the University of San Francisco and Community Recovery Resources (CoRR) prior to
the project’s implementation. The project was in compliance with the Health Insurance
Portability and Accountability Act (HIPAA) and any and all patient names and/or identifiers
were excluded. The protection of participants physical and psychological well-being was of
utmost importance throughout the entirety of this project. There were no conflicts of interest.
When reflecting on the Jesuit values, the value of “men and women for and with others” and
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“contemplative in action” (Regis University, 2018) was demonstrated in this clinical
improvement project. The value of “men and women for and with others” is demonstrated
through being of service and supporting the “poor and marginalized” (Regis University, 2018).
The purpose of this project was to improve health outcomes and increase access to medicationassisted therapy (MAT) to an underserved population with a goal of being of service and
supporting those with opioid use disorder with evidenced based practices as this population are
often marginalized by society. Furthermore, the value of “contemplative in action” can be seen in
this project through the identification of a social problem and the creation of an action plan to
address this issue.
The first provision of the American Nurses Association (ANA) Code of ethics states that
the “nurse practices with compassion and respect for the inherent dignity, worth and unique
attributes of every person” (American Nurses Association, 2015). Throughout the course of this
paper and project implementation, interventions and care have been provided with compassion
and respect for the patient and their dignity and worth has been recognized and preserved.
Section III: Results
Patient Satisfaction Surveys. A five-question paper patient satisfaction survey was
obtained one month after the implementation of the project in February 2019 to provide feedback
regarding the MAT services provided on the Tuesday and Wednesday groups yielding 17
respondents (Appendix O). The first question asked, “Would you rate the quality of service you
have received on the Wednesday MAT group as “excellent”? Answer choices included “yes”, “no”
or “if not, what suggestions do you have to improve the program?” which included space for a
narrative response. One hundred percent of the respondents indicated that the quality of service
they had received on the Wednesday MAT groups was “excellent” and two patient wrote a
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narrative response in addition to circling “yes”, with one patient indicating that “having everyone
[there] is perfect for what [they] need right now” and one patient suggesting “less cross
talk/interruptions” (Table 1).

Table 1

Q1: Would you rate the quality of service you
have received on the Wednesday MAT group as
"excellent"?
Suggestions for Improvement

2

No

0

Yes

17
0

2

4

6

8

10

12

14

16

18

The second question asked, “Has the MAT program at CoRR met your needs?” The
answer choices included “none of my needs have been met”, “only a few of my needs have been
met”, “most of my needs have been met” and “almost all of my needs have been met.” Seventysix percent of respondents indicated “almost all of my needs have been met” and 24% indicated
that “most of my needs have been met” (Table 2).
Table 2
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Q2: Has the MAT program at CoRR met your
needs?
14
12
10
8
6
4
2
0

13

0

0

None

Few

4
Most

Almost All

The third patient satisfaction survey question asked, “Have the services you received at
CoRR helped you to deal more productively with your drug and/or alcohol program?” The
answer choices included “No, they seemed to make things worse”, “No, they didn’t really help”,
“Yes, they helped somewhat” and “Yes, they helped a great deal.” Eighty-eight percent of
respondents indicated that the services they received at CoRR helped them “a great deal” in
dealing more productively with their drug and/or alcohol program and 12% indicated that the
services they received at CoRR “helped somewhat” (Table 3).

Table 3

Q3: Have the services you received at CoRR
helped you to deal more productively with your
drug and/or alcohol program?
Helped Great Deal
Helped Somewhat
Did not Help
Made Things Worse
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The fourth patient satisfaction survey question asked, “How satisfied are you with the
amount of help you have received?” The answer choices included “very dissatisfied”,
“indifferent or mildly dissatisfied”, “mostly satisfied” or “very satisfied.” Seventy-one percent of
respondents indicated that they were “very satisfied” with the amount of help they had received
and 29% indicated that they were “mostly satisfied with the amount of help they had received
(Table 4).

Table 4

Q4: How satisfied are you with the amount of
help you have received?
Very Satisfied
Mostly Satisfied
Indifferent / Mildly Dissatisfied
Very Dissatisfied
0
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The last question asked if the respondent had “any suggestions for how the MAT program
at CoRR can improve” and “What [they] liked about the program or think has been successful thus
far?” and a space was provided for a narrative response. When examining the narrative responses
to this question, several themes emerged such as the offering of additional MAT group days/times,
more support (i.e. help with housing, finances, etc.) and many respondents left a positive response
indicating that the program has met their needs. In addition, themes that emerged when patients
discussed the benefits of MAT were it “gives you your life back”, controls cravings, decreases
drug seeking behaviors, saves money, improved health and improved relationships (Curtis, Knapp
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& Otten, 2019). At the time of collection for the initial patient satisfaction survey, the Wednesday
MAT group had an average of 103 participant “sober days” (3 months).
A second patient satisfaction survey was collected at the completion of the DNP project in
April 2019 yielding 25 respondents. The first question asked, “Would you rate the quality of
service you have received on the Wednesday MAT group as “excellent”? Answer choices included
“yes”, “no” or “if not, what suggestions do you have to improve the program?” which included
space for a narrative response. One hundred percent of the respondents indicated that the quality
of service they had received on the Wednesday MAT groups was “excellent” (Table 5).
Table 5

1. Would you rate the quality of service you
have received on the Wednesday MAT group as
"excellent"?
30
25
25

20
15
10
5

0

0
Yes

No

The second question asked, “Has the MAT program at CoRR met your needs?” The answer
choices included “none of my needs have been met”, “only a few of my needs have been met”,
“most of my needs have been met” and “almost all of my needs have been met.” Eighty-eight
percent of respondents indicated that the MAT program at CoRR had met “almost all of my needs
have been met” and 12% indicated that “most of my needs have been met” (Table 6).
Table 6
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2. Has the MAT program at CoRR met your
needs?
25
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15
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0
None
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Almost All

The third patient satisfaction survey question asked, “Have the services you received at
CoRR helped you to deal more productively with your drug and/or alcohol program?” The answer
choices included “No, they seemed to make things worse”, “No, they didn’t really help”, “Yes,
they helped somewhat” and “Yes, they helped a great deal.” Ninety-six percent of respondents
indicated that the services that they received at CoRR helped them “a great deal” in dealing more
productively with their drug and/or alcohol program and 4% of respondents indicated that the
services they received “helped somewhat” (Table 7).

Table 7

3. Have the services you received at CoRR
helped you deal more productively with your
drug and/or alcohol program?
Greatly Helped
Somewhat Helpful
Unhelpful
Worse
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The fourth patient satisfaction survey question asked, “How satisfied are you with the
amount of help you have received?” The answer choices included “very dissatisfied”,
“indifferent or mildly dissatisfied”, “mostly satisfied” or “very satisfied.” One respondent left
this question blank thus there were only 24 responses total for this question. Ninety-two percent
of respondents indicated that they were “very satisfied” with the amount of help they had
received and 8% indicated that they were “mostly satisfied with the amount of help they had
received (Table 8).
Table 8

4. How satisfied are you with the amount of help
you have received?
Very Satisfied
Mostly Satisfied
Indifferent or Mildly Dissatisfied
Very Dissatisfied
Unanswered
0

5

10

15

20

25

The last question asked if the respondent had “any suggestions for how the MAT program
at CoRR can improve” and “What [they] liked about the program or think has been successful thus
far?” and a space was provided for a narrative response. When answering what they liked about
the program or think has been successful, many of the respondents wrote that they were thankful
for the staff and felt like they “really care” and expressed that they were “getting their life back.”
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In addition, many expressed that they felt the amount of support they received was a success of
the program. Respondents also indicated that they felt the MAT program helped to lessen their
cravings and keep them sober and that the program was patient centered and need based.
Furthermore, several respondents indicated that they liked interacting with people that were also
on Suboxone. Suggestions from respondents for how the MAT program at CoRR can improve
were to offer more group times and provide more information on Suboxone.
Provider Satisfaction Survey. An electronic, anonymous, provider satisfaction
survey regarding the MAT Group program was created using Survey monkey and sent to the
Medical Director, Nurse Practitioner, Substance Abuse Counselor and Clinical Coordinator at the
completion of the DNP project at completion of the DNP project in April 2019 (Appendix P). The
survey included three questions that allowed for the providers to answer in the narrative format.
The survey yielded three responses.
The first question asked what qualities the provider felt made a successful MAT program.
The providers indicated that consistency, organization, adherence to clinical standards, patient
centered care, boundaries, holistic care, flexibility and sustainable billing practices contributed to
a successful MAT program.
The second question asked what qualities providers felt made the MAT program at CoRR
successful. The respondents indicated that the quality of care provided by the staff, teamwork,
adherence to clinical standards, patient centered care, flexibility, active group meetings with
counselors and providers, and comprehensive care for those with opioid use disorder made the
MAT program at CoRR successful.
The last question asked that providers indicate what they would like to see improve or
change in regard to the MAT program at CoRR. Providers indicated that they would like to see the
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implementation of electronic medical records and improved billing procedures. One respondent
indicated they would like more extensive training on the policy and procedures at the clinic. In
addition, respondents also indicated they would like to see the replication and expansion of the
program in other areas and closer collaboration with other federally qualified health centers
(FHQC’s). Lastly, the providers would like improved access to psychiatric care for patients and
improved communication with the local hospital.
Demographic and Benchmark Data. At the initiation of the DNP project there were 47
patients identified as eligible for participation in the MAT group program. The final number of
participants were 35 as 12 never attended a MAT group on either day and were lost to follow-up
or chose not to participate in the program. Patients were counted as being retained in the MAT
group if they attended >2 MAT groups on either Tuesday or Wednesday. The data indicates that
74% of patients were retained in the MAT group program at CoRR (Appendix P) which exceeds
the recommended benchmark goal of 60% presented in the literature. There were 21 patients who
attended the first MAT Wednesday group which exceeded the established objective for the project.
To accommodate the increased number of MAT patients who expressed interest in this new group
format an additional MAT group was created on Tuesdays. On average, there was about 12 patients
who attended each respective MAT group. Participants were predominantly male at 63% male and
37% female and the most common age range were those between the ages of 26-34 years old
(Table 5).
Table 5
Demographic Data MAT Group (N=35)
Gender
Male

22 (63%)
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13 (37%)

Age
18-25 years old

2 (6%)

26-34 years old

21 (60%)

35-55 years old

11 (31%)

55 or older

1

(3%)

The Nurse Practitioner obtained demographic data in the Summer of 2018 in regard to
MAT patient race/ethnicity and Medi-Cal eligibility which can be found in the table below (Table
6).
Table 6
MAT Demographic Data Summer 2018
Race/Ethnicity
White, non-Hispanic

41 (98%)

Other

1 (2%)

Medi-Cal Eligible
Yes

27 (64%)

No

15 (36%)

(Curtis, Knapp & Otten, 2019)
Section IV: Discussion
Summary
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The implementation of the DNP project occurred over the course of four months at the
CoRR Grass Valley campus. The over-arching aim of this DNP project was to improve health
outcomes among underserved residents of Nevada county by increasing access to interprofessional team-based MAT for opioid use disorder through the development of evidence
based, interdisciplinary, nurse-managed MAT services through the initiation of the pilot program
for the newly developed MAT patient delivery system and the development of evidence-based
nurse practitioner process protocols. A measure of the success of the program and increasing
access to MAT services for this patient population, was meeting the benchmark goal of 60% for
patient retention in the program. The data from this project indicated that there was a 74%
retention rate in the MAT group program at CoRR which meets the benchmark goal of 60%
suggested in the literature. In addition, the targeted patient population were underserved
members of a non-metropolitan community and as previously discussed, Nevada and Placer
counties have high rates of opioid use disorder with limited access to MAT services. The project
implementation served patients with opioid use disorder from both counties which met the goal
of increasing access to MAT services for this under resourced group.
Furthermore, the initial patient satisfaction survey results regarding the nurse managed,
interdisciplinary MAT group were positive with 100% of the respondents indicating that the
quality of service they had received on the Wednesday MAT groups was “excellent” and 76%
respondents indicated “almost all of my needs have been met” by the MAT program at CoRR. In
addition, a majority of the patients indicated that the MAT program and helped them deal more
productively with their drug and/or alcohol program and were satisfied with the amount of help
that they had received. Due to the overwhelming positive feedback from the MAT patients at
CoRR, a second team-based MAT group was added on Tuesdays. In addition, the Medical
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Director at CoRR indicated that there were plans to expand the newly developed collaborative
MAT group format to other CoRR campuses.
The data indicates a significant need for nurse-managed community-based MAT services,
especially in non-metropolitan Northern California counties, where opioid overdose rates remain
high and access to services limited. This DNP project has assisted in bringing needed MAT
services to this underserved non-metropolitan community, and in turn improved health
outcomes, where the number of residents with opioid use disorder remains high.
Interpretation
The findings of this DNP quality improvement project found positive and successful
outcomes from the nurse-managed community-based medication assisted treatment services for
underserved patients with an opioid use disorder in a non-metropolitan Northern California
county. The findings were consistent a study conducted by Jones (2018) stating that MAT in
conjunction with psychosocial treatment has been shown to be the most effective evidenced
based treatment option for this patient population (Jones, 2018).
The treatment of opioid use disorder is multidimensional and requires a comprehensive,
interdisciplinary approach when providing MAT services. Employing nurse-managed,
collaborative community-based medication treatment services for underserved patients with
opioid use disorder in non-metropolitan communities allows for integrative treatment and
improved health outcomes and patient satisfaction. This supports the ecological framework that
guided this DNP project as the fundamentals of this perspective are supporting all levels of a
health problem. The interventions of this project addressed the intrapersonal, interpersonal,
institutional/organizational and community factors of the individual with opioid use disorder.
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Although the research discussed in this DNP paper states that best practice is MAT in
conjunction with psychosocial treatment, some recent research brings this idea into question. The
field of substance abuse, and medication assisted treatment, is ever evolving and remains new
and thus further research is needed regarding the role of behavioral health in conjunction with
MAT. In addition, further research is needed regarding nurse-managed, interdisciplinary
medication assisted treatment for opioid use disorder in underserved non-metropolitan
communities who remain at high risk.
Limitations
A limitation of this DNP project was the shortage of available providers/prescribers who
possessed a waiver to prescribe or dispense buprenorphine. The Drug Addiction Treatment Act
of 2000 (DATA 2000) requires that qualified practitioners apply for a waiver to treat opioid
dependency with approved buprenorphine products after meeting specific criteria. Once a waiver
is obtained, they can treat no more than 30 patients at a time within the first year (Substance
Abuse and Mental Health Services Administration, 2019). This limited the amount of MAT
patients that could be seen as there were at minimum two providers present at a time who carried
a waiver to prescribe Buprenorphine limiting the number of patients that could be prescribed
opioid agonist treatment to a maximum of 60. Strategies to mitigate this potential barrier would
be to increase the MAT trainings for providers to ensure adequate staffing and collaborate with
the CEO and other stakeholders to ensure continued staff development and growth and support
for all team members (SAMHSA-HRSA Center for Integrated Heath Solutions, 2014)
Another limitation of this project were the attitudes and beliefs of some counselors and
members of other support groups in regard to the use of medications in the treatment of opioid
use disorder (i.e. buprenorphine). In speaking with the MAT patients during groups and
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privately, multiple patients shared that they were told that because they were on Buprenorphine
as adjunctive therapy in the treatment of their opioid use disorder they were not considered to be
“sober” and they were discouraged from using the medication. To address this potential barrier,
providers could provide education to all members of the health care team regarding the
medications that are used in MAT, present the data supporting its use, and reinforce education
provided to patients regarding the use of medication to support their recovery.
The third limitation of the project was the time frame for delivery. Although the project
was implemented over a four-month time period, the DNP student/project manager was only able
to attend 2-3 Wednesday MAT groups a month due to scheduling conflicts with her primary
employer. The added Tuesday MAT group was not attended by the DNP student. This could
have had an effect on the results of the project and being present for the implementation of all
MAT groups would have been ideal.
Conclusion
MAT has proven to be the most effective evidence-based treatment option for patients
with opioid dependence combined with psychosocial treatment. Treatment of opioid misuse
disorder with buprenorphine and naloxone and/or buprenorphine has been proven to be safe and
an effective treatment option in the office-based setting to decrease opioid use and cravings. It
can also be correlated to lower transmission rates of communicable diseases such as hepatitis c
and decreased numbers of heroin overdose deaths. In addition, recent data suggests that counties
with high overdose rates, such as certain rural Northern California counties, have decreased
access to opioid treatment programs. The implementation of a nurse managed, community-based
MAT program for underserved patients in non-metropolitan communities would assist in
alleviating this issue by increasing access to these much-needed services.
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This nurse-managed, community-based care model for providing MAT services to
underserved patients in nonmetropolitan areas combines best practice in treating opioid use
disorder and provides comprehensive and collaborative care which yields positive health
outcomes and supports recovery. This is further supported by the positive findings of this project
with a MAT retention rate which met the benchmark goal and overwhelmingly positive results of
the patient satisfaction survey that was administered regarding the MAT services provided. The
project implementation and model are reproducible as evidenced by addition of the Tuesday
MAT group as well as plans to expand the newly developed MAT group to other campuses
within the CoRR organization. Particularly, the role of the Nurse and Nurse Practitioner is
essential to connecting these high-risk, vulnerable communities with needed MAT services to
improve health outcomes and counteract the devastating effects of the opioid epidemic.
Due to the new and evolving nature of the field of substance abuse and medication
assisted treatment, it would be beneficial to obtain further research regarding best practices for
providing MAT services to underserved non-metropolitan communities.
Section V: Other Information
Funding
This DNP project was funded through personal savings as indicated in the budget. The
clinic site implementation site, Community Recovery Resources (CoRR), receives funds through
the Hub and Spoke grant through Aegis. There are no other financial disclosures related to this
DNP project.
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Appendix B: Letter of Approval from Community Recovery Resources (CoRR) Grass Valley

To Whom It May Concern:
Lauren Knapp, University of San Francisco BSN-DNP/FNP student, has been approved to
initiate her DNP project regarding the development and implementation of nurse-managed,
community-based medication assisted treatment services at the Community Recovery Resources
Grass Valley campus.
The student is granted permission to utilize the conference room and clinical space at the Grass
Valley campus for the implementation of her DNP clinical improvement project.
Sincerely,

Michelle Otten
Medical Services Coordinator,
Grass Valley Residential
Community Recovery Resources
www.corr.us
Tel: (530) 273-9541 ext. 234
Fax: (530) 271-7036
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Appendix C: SWOT Analysis

Strengths
• Addresses the problem of inadequate
access to MAT services for opioid
dependent patients in non-metropiltan
communities
• The potential impact the
implementation of nurse-managed
MAT services would have on illicit
and prescription opiod related deaths
• The potential cost savings in
decreased uilization of inpatient and
detoxification services and
• The potential for decreased rates of
communicable diseases (i.e. Hepatitis
C)
• Increased distribution of Narcan kits
to the community and high risk
groups

Opportunities
• Provide increased access to MAT
services to a high risk nonmetropolitan community
• Provide education to patients, family
and the community regarding the use
of Narcan and it's life-saving capability
• Reduce the number of illicit and
prescription related deaths
• Continued H&S grant funding for
MAT services
• Reducttion in the transmission of
communicable diseases in this high risk
population through opioid agonist
medication adherence and education

Weaknesses
• Lack of patient transportation to
CoRR Grass Valley for treatment
• Patients not covered by the H&S
grant unable to pay for MAT services
• Lack of waivered prescribers to meet
the treatment needs of the patients
• Patient adherence to Suboxone
induction/maintenance therapy
• Patient demographics (i.e. unstable
housing, distance from clinic, lack of
support system)

Threats
• Loss of H&S funding
• Opioid dependent patients in need of
MAT services unable to access
treatment
• Pharmacy out of stock of opioid
agonist medication
• Patient leaves MAT treatment
• No change in illicit and opioid related
deaths
• Loss of waivered prescibers
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Appendix F: Budget and Cost Benefit Analysis

Direct Costs
Item Description
Materials (patient and provider
surveys, handouts, 24 pk box of
ballpoint pens)

Coffee and Donuts on the first
day of the MAT Wednesday
Pilot Program

NP Travel Cost (mileage/gas)

Indirect Costs
Item Description
NP Project
management/implementation
TOTAL PROJECT
EXPENSES
(Direct + Indirect Costs)
Budget

Unit Cost
$59.99 for 100 full-color,
single sided flyers

Total Cost
$66 (Paid for by NP)

$5.79 for 24 pk box of black
Bic ballpoint pens
Starbucks Coffee Traveler
$50 (Paid for by NP)
$12.95 per box (Serves 12)
(2 boxes = $26)
$20 for 2 dozen Donuts
from B.J. Cinnamon Donut
Shop in Folsom, CA
98 miles/week
$240 (Paid for by NP)
$30 per week (2
Wednesdays/month) x 4
months
Total $356
Unit Cost
$61/hour x 8 hrs/week (2
Wednesdays/month) x 4
months

Total Cost
$3,904 (NP services/project
management provided at no
cost)
$4,260

Societal Costs of Prescription Opioid Abuse, Dependence and Fatal Overdose, United
States (Millions of 2013 Dollars)
Nonfatal Costs
Costs (Range based on 95% CI of
prevalence)
Health care
$26, 075 ($21,372-$30,778)
Substance Abuse Treatment
$2,820
($2,567-$3,245)
Criminal Justice
$7, 654
(public sector costs)
Lost Productivity
$20, 441 (%17,286-$23,751)
Total Nonfatal Costs
$56,990
($48,879-$65,428)
Fatal Costs
$21,513
($21,182-$21,844)
Total Nonfatal and Fatal Costs
$78, 503
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Florence, C., Luo, F., Xu, L., & Zhou, C. (2016). The economic burden of prescription opioid
overdose, abuse and dependence in the united states, 2013. Medical Care, 54(10), 901-906.
•

Cost Benefit Calculation
Total nonfatal cost of prescription opioid misuse $58 billion
o This number includes:
▪ Increased healthcare and substance abuse treatment costs by $29.4 billion
▪ Increased criminal justice costs by $7.8 billion
▪ Reduced productivity among those who do not die of overdose by $20.8
billion (2015)
o Total nonfatal cost of $58 billion  1.9 million people in the U.S. with a
prescription opioid disorder in 2013 = average cost of $30,000
*Average cost estimates for prescription opioid disorders only
(Council of Economic Advisors, 2017)
Cost Benefit Ratio

Average nonfatal cost of a person with a
prescription opioid disorder in the U.S. in 2013
Projected cost for project implementation for one
year

 $ 30,000
$ 12,779
$30,000/$12,779 = 2.35
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Appendix G: Work Breakdown Structure

The Development and Implementation of NurseManaged Community-based Medication Assisted
Treatment Services for an Underserved NonMetropolitan Northern California Community

Phase 1
Conduct research on
opioid epidemic in the U.S.
and best practices for
MAT services

Phase 2
Meet with the Medical
Director, NP, PA and
Clinical Coordinator and
stakeholders at CoRR to
propose the clinical
improvement project

Phase 3
Develop updated MAT
prescribing policies for
opioid agonist medications
(i.e. Suboxone), patient
and provider resources,
structured Wednesday
MAT group classes

Phase 4
Evauate the success of the
project implementation
through established
outcome measures and
patient and provider
satisfaction surveys
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Appendix H: Communication Plan
Information

Audience

When

DNP project
development and
coordination
DNP project status
and any barriers
encountered
DNP project
revisions
DNP project
milestones

DNP Chair, CoRR
Clinical Coordinator,
CoRR MD, FNP, PA
DNP Chair, CoRR
Clinical Coordinator

Weekly

Weekly

In-person meeting,
Email, Cell phone

DNP Chair, CoRR
Clinical Coordinator
DNP Chair and
Committee Member

As needed

In-person meeting,
Email, Cell phone
In-person meeting,
Zoom, Email

Monthly

Communication
Method
In-person meeting,
Email, Cell phone
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Appendix I: Gap Analysis

Desired State

Current State

Action Plan

• Increase access to nurse managed, community based medicationassisted therapy for opioid dependence at Community Recovery
Resources (CoRR) Grass Valley to decrease the rates of illicit and
prescription opioid misuse and prescription opioid related death
rates and optimize and support the patient's overall health and
well-being.

• Community Recovery Resources (CoRR) Grass Valley is
currently developing their medication-assisted therapy program
for opioid dependence, through the H&S Grant funding, and
there is an opportunity to incease access to these services for
those that are opioid dependent in the community.

• Conduct a review of the literature for medication-assisted therapy best
practices, identify demographic data related to illicit and prescription
opioid misuse and related death rates to idenitfy high risk populations
• Meet with CoRR treatment team and stakeholders and present
proposed implementation project
• Develop updated prescribing policies, patient and provider resources,
structured Wednesday clinic days w/interprofessional team
• Evaluate the effectivess of the project by number of patients seen,
responses from the patient and provider satisfaction survey provided,
the retention rate for patients in the program with a benchmark goal
of 60% and this information will be assembled over a three month
period.
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Appendix J: GANTT Chart

10/1/18
Conduct a literature review
Meet with stakeholders, assemble Committee Chair and
Committee Member
Identify patients to be enrolled in MAT Wednesday Groups
Develop updated MAT group policies and workflows,
updated prescribing policies, process protocols and patient
and provider resources
Project Implementation

Data collection and analysis
Complete written DNP project and disseminate results to USF
faculty

11/20/18

1/9/19

2/28/19

4/19/19
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Appendix K: MAT Wednesday Pilot Program Schedule, CoRR Grass Valley
MAT Wednesday Pilot Program Schedule
CoRR Grass Valley
0800-0900

Flash Meeting, MAT meeting

0900-0930

Patient’s arrive, UDS testing (to be completed before or after MAT class)

1000-1100

MAT Group Class
Location: Conference room #104
Instructors: Steve and Natalie
6-10 patients initially
Mandatory attendance—patient unable to receive medication refill if not in
attendance

1100-1130

Patient UDS testing, if not already completed prior to MAT class
Patients that have any concerns with their maintenance dose of Suboxone or any
clinical concerns can be seen by a provider at this time

1200-1300

Lunch

1300-1700

Clinic

Lauren (USF FNP student) will bring refreshments to the first group and patients can be
given an extra gas card for attendance.
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Appendix L: Updated Maintenance Therapy Suboxone Progress Note for MAT Group
Community Recovery Resources
Maintenance Therapy Progress report – Suboxone (buprenorphine/naloxone)
Community Recovery Resources
159 Brentwood Drive
Grass Valley, CA 95945
Ph. (530) 273-9541 / Fax (530) 273-7740

Scott Kellerman MD
Ca License #
DEA:
DEA:

Patient Name: ___________________________ DOB: ___________ Date: ___________
Prior drug of choice: __________________________ COWS: __________
Chief Complaint_______________________________________________________________
HPI:
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________

Urine Drug Screen results:
__________________________________________________________
Patient indicates they would like to be seen by provider after MAT group? □ yes □ no
I feel like using right now: not at all – mild – moderate – severe
I rate my level of withdrawal: not at all – mild – moderate – severe
Suboxone dose: ________mg Taken: Once daily Twice daily Three times daily
 strips
 tabs
Refilled at what interval: ____________
Preferred pharmacy: ______________________________________________
Date of last Cures report: __________________
Have you used alcohol since last visit: Yes No
If “Yes” how much and when: _______________________________________
Appearance/mental status_______________________________________________________
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Neuro/Psyche (tremor/jerks/follows commands) ______________________________________

Recent Lab Results: _________________________________________________________
Diagnosis:
1._____________________________________________________________________
2._____________________________________________________________________
3._____________________________________________________________________
4._____________________________________________________________________
Narcan available? Yes No
Lab Ordered: Yes No
Urine Drug Test (5-8 Items), CBC/differential, comprehensive chemistry panel, GGT, hepatitis B
surface antigen - (if positive - reflex to hepatitis quantitative HBV DNA levels), hepatitis B core
antibody - (if positive - reflex to quantitative HBV DNA levels), hepatitis B surface antibody ,
Hepatitis C antibody - (reflex to quantitative HCV RNA level if positive), Chlamydia/Gonorrhea,
HIV, RPR
If female – pregnancy test. Additional labs:
_____________________________________________
Treatment: (drug/dose/frequency/duration)
1._Suboxone:
_____________________________________________________________________________
2.____________________________________________________________________________
3.____________________________________________________________________________
4.____________________________________________________________________________
5.____________________________________________________________________________
Notes:
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
Consults/therapy/counseling ordered: Yes
If Yes to whom? ______________________

No

Referral to Primary Care: Yes No Pt has ongoing outpatient care Provider
If Yes to whom? _______________________
Return to clinic: 1 week 2 weeks 3 weeks 4 weeks prn other_____________________

Provider Signature: ______________________________________
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Appendix M: CoRR Wednesday MAT Group Protocol

Community Recovery Resources (CoRR)
Wednesday MAT Group Protocol
I.

Criteria for Wednesday MAT group participation
A.
The patient meets DSM 5 diagnostic criteria for moderate or severe opioid use
disorder
B.
The patient has completed the induction phase of Suboxone and has
demonstrated relative stability on their maintenance dose of Suboxone
C.
The patient does not have any prior job commitments that would hinder their
ability to be present for the Wednesday MAT group
D.
Attendance for Wednesday MAT group is mandatory, patient will be unable
to receive medication refill if not in attendance.

II.

Workflow for Wednesday MAT group
A.
Each patient will check in 15-30 minutes prior to the start of each group
and provide a urine sample for the urine drug screen (UDS). If the patient is
unable to provide a urine sample prior to the start of the group, a urine sample
will be required for the UDS immediately following the group.
1.
All urine drug screen results will be recorded and given to the
health care provider as soon as they are available.
B.
The health care team comprised of the Counselor(s), MAT Program Director,
Medical Assistant, Physician, Nurse Practitioner and Physicians Assistant will all
be present during the Wednesday MAT group.
C.
All patient’s charts who are participating in the Wednesday MAT group will be
pulled and brought to conference room number 104 at the start of each group and
be accessible to the health care provider(s) to chart assessments, progress notes
and write medication refill orders.
D.
Prior to the start of the group, patients will complete a short questionnaire
regarding any issues they are having with recovery, cravings/withdrawal
symptoms, request for a change in medication dosage and/or a request to meet
with their health care provider after the group. After the questionnaire is
completed by the patient, each questionnaire will be given to the respective health
care provider.
E.
MAT group meeting will be conducted by Counselor (Natalie or Steve)
F.
Following the MAT group, patients who requested to see the health care provider,
or have an existing appointment with the provider, will be roomed and seen.
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Appendix N: Standardized Procedures for the Nurse Practitioners at Community Recovery
Resources (CoRR)

STANDARDIZED PROCEDURES FOR THE
NURSE PRACTITIONERS AT
Community Recovery Resources (CoRR)
Grass Valley Campus
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INTRODUCTION TO THE STANDARDIZED PROCEDURES

The purpose of these Standardized Procedures is to define the scope of practice of
Nurse Practitioners at Community Recovery Resources (CoRR) in order to meet the legal
requirements for the provision of health care by nurse practitioners. They are established to
assist all health care providers with an understanding of the role and scope of practice of the
nurse practitioner and to provide a safeguard so that providers and patients alike may be assured
of the best health care possible.
These Standardized Procedures are based on the Guidelines established by the Board of
Registered Nursing and the codes and regulations circumscribing California nurse practitioners
(collectively referred to as the Nursing Practice Act). In order to provide the highest standard of
care, these Standardized Procedures incorporate the following qualities:
ADAPTABILITY, in order to allow for the unique management needs of each individual
patient;
FLEXIBILITY, to accommodate the rapidly changing and complex nature of the health care
field and to acknowledge that medicine is not an exact science;
PRACTICALITY, in order to be useful in a setting that must incorporate a variety of
educational backgrounds and personal management styles; and
SPECIFICITY, to address the intent of the Standardized Procedure Guidelines, the codes
regulating nurse practitioners and to protect the health care consumer.

The Standardized Procedures consist of the following:
GENERAL POLICIES: Define the general conditions of and give authorization to the
nurse practitioner to implement the Standardized Procedures.
HEALTH CARE MANAGEMENT STANDARDIZED PROCEDURES: Delineate the
medical functions requiring a standardized procedure and, using policies and protocols,
define the circumstances and requirements for their implementation by the nurse practitioner.
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STATEMENT OF APPROVAL AND AGREEMENT
This document was jointly developed and approved by the CoRR Medical Director, Dr. Scott
Kellerman, and the clinical practice team, for Nurse Practitioners in accordance with the codes
regulating nursing practice, on ____[date]___________________.
Signature on this statement implies
•
Approval of the Standardized Procedures and all the policies and protocols contained in
this document.
•
Agreement to maintain a collaborative and collegial relationship.
•
Agreement to abide by the Standardized Procedures in theory and practice.

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date

______________________________________________________________
Name/Title
Date
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GENERAL POLICIES
It is the intent of this document to authorize nurse practitioners at Community Recovery
Resources (CoRR) to implement the Standardized Procedures without the immediate supervision
or approval of a physician. The Standardized Procedures, including all the policies and protocols,
are defined in this document and will be referred to generally as the "Standardized Procedures".

DEVELOPMENT, APPROVAL, REVISION AND REVIEW
The Standardized Procedures have been collaboratively developed and approved by the Nurse
Practitioners, Medical Director and CEO of CoRR. Review, and if necessary, revision, of the
Procedures will be done yearly by the Nurse Practitioner, the Medical Director and the CEO at
CoRR. The completion of these tasks, including notification of revisions, is the responsibility of
the Nurse Practitioners, the Medical Director and the CEO at CoRR.
AGREEMENT
All nurse practitioners and associate physicians will signify agreement to the Standardized
Procedures following the approval process. Signature on the Statement(s) of Approval and
Agreement implies the following: approval of all the policies and protocols in this document, the
intent to abide by the Standardized Procedures, and the willingness to maintain a collegial and
collaborative relationship with all the parties.
SETTING
The nurse practitioners will perform these Standardized Procedures at Community Recovery
Resources (CoRR), in Auburn, Grass Valley, Lincoln, Roseville, Kings Beach and Truckee
campuses.
RECORD OF AUTHORIZED NURSE PRACTITIONERS
The Statement of Approval and Agreement signed by the nurse practitioners will act as the
record of nurse practitioners authorized to implement the Standardized Procedures.
EDUCATION AND TRAINING
The nurse practitioners must have the following:
• Possession of a valid California License as a Registered Nurse.
• Certification by the State of California, Board of Registered Nursing as a Nurse
Practitioner.
• Furnishing Number.
• DEA Number.
• Certification by a national certifying body (AANP or ANCC).

THE DEVELOPMENT AND IMPLEMENTATION OF

78

EVALUATION OF CLINICAL CARE
Evaluation of the nurse practitioner will be provided in the following ways:
INITIAL EVALUATION
•

Performed at 3 and 6 months through feedback from colleagues and chart review of patient care
delivered during the evaluation period.

CONTINUING EVALUATION
•
Annual evaluation based on feedback from colleagues and chart review of patient care
delivered during the evaluation period.
•
Verification of current licensure and certifications.
PATIENT RECORDS
The nurse practitioner will be responsible for the preparation of a complete medical record for
each patient contact per existing office policies.
SUPERVISION
The nurse practitioner is authorized to implement the Standardized Procedures in this document
without the direct or immediate observation, supervision or approval of a physician. Physician
consultation is available at all times, either on-site, by phone or electronically.
CONSULTATION
The nurse practitioner will be providing health care as outlined in this document. In general
communication with a physician will be sought for all the following situations, and any others
deemed appropriate. Whenever a physician is consulted, a notation to that effect, including the
physician's name, must be made in the chart.
•
•
•
•
•
•

Whenever situations arise which go beyond the intent of the Standardized Procedures or
the competence, scope of practice, or experience of the nurse practitioner.
Whenever patient conditions fail to respond to the management plan as anticipated.
Any patient with acute decompensation or rare condition.
Any patient conditions which do not fit the commonly accepted diagnostic patterns for a
disease or disorder.
At the patient's, nurse practitioner's or physician's request.
All emergency situations after initial stabilizing care has been started.
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HEALTH CARE MANAGEMENT - PRIMARY CARE

POLICY
Primary Care includes acute and episodic conditions, chronic conditions, and health care
maintenance. Medication-based therapies for opioid use disorder and substance use disorder
detoxification are included under primary care in this standardized procedure. The nurse
practitioner is authorized to diagnose and manage Primary Care conditions under the following
protocols:

PROTOCOLS
1) Assessment and treatment plan is developed consistent with accepted clinical guidelines
available through the practice resources listed in this document.
2) Lab work and diagnostic studies ordered are appropriate to the condition being evaluated
and consistent with internal practice policies
3) Durable medical goods and therapies ordered, such as physical therapy, occupational
therapy, dietary counseling and psychological services, are appropriate to the condition
and consistent with internal practice policies.
4) Patient education and follow up is provided as appropriate.
5) All other applicable Standardized Procedures in this document are followed during health
care management.
6) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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HEALTH CARE MANAGEMENT - SECONDARY CARE

POLICY
Secondary Care conditions are unfamiliar, uncommon, unstable or complex conditions. The
nurse practitioner is authorized to evaluate and treat Secondary Care conditions under following
protocols:

PROTOCOLS
1) Assessment to the level of surety plus appropriate differential diagnosis.
2) A physician is communicated with regarding the evaluation, diagnosis and/or treatment
plan.
3) Management of the patient is either in conjunction with a physician or by complete
referral to a physician or other treatment center.
4) The physician is notified if her/his name is used on a referral to a specialty physician or
department.
5) The consultation or referral is noted in the patient's chart including name of physician.
6) All Secondary Care charts are co-signed by a physician.
7) All other applicable Standardized Procedures in this document are followed during health
care management.
8) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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HEALTH CARE MANAGEMENT - TERTIARY CARE

POLICY
Tertiary Care conditions are acute, life-threatening, emergency conditions. The nurse
practitioner is authorized to evaluate Tertiary Care conditions under the following protocols:

PROTOCOLS
1) Initial evaluation and stabilization of the patient may be performed with concomitant
notification of a physician or emergency department, and immediate referral.
2) The referral is noted in the patient's chart including name of physician and/or facility
referred to.
3) All other applicable Standardized Procedures in this document are followed during health
care management.
4) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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PROCEDURES AND MINOR SURGERY

POLICY
The nurse practitioner may perform the listed procedures under the following protocols:
•
•
•
•
•
•
•
•

Chemical or electrocautery of external, non-facial, non-malignant lesions less than
1cm in size, e.g. warts.
Foreign body removal, simple removal from the skin.
Epidermal cyst removal (non-facial) less than 3 cm in size.
Incision and drainage of non-facial abscess less than 5 cm in size.
Suture non-facial laceration less than 5 cm in size.
Toenail removal.
IUD insertion.
Nexplanon insertion.

PROTOCOLS
1) The nurse practitioner has been trained to perform the procedure(s), has been
observed satisfactorily performing the procedure(s) by another provider competent in
that skill, and continued competency is assessed per written criteria.
2) The nurse practitioner is following standard medical technique for the procedures as
described in the Resources listed in this document.
3) Appropriate patient consent is obtained before the procedure.
4) All other applicable Standardized Procedures in this document are followed during
health care management.
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation,
Patient Records, Supervision and Consultation in these Standardized Procedures are
in force.
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FURNISHING DRUGS AND DEVICES

POLICY
The nurse practitioner is authorized to furnish drugs and devices under the following protocol:

III. PROTOCOL
1) The nurse practitioner has a current furnishing number.
2) The Standardized Procedure was developed and approved collaboratively by the medical
director and nurse practitioner clinical care team.
3) All drugs and devices ordered are limited to the recommendations in the clinical
resources listed in this document.
4) The drugs and devices ordered are consistent with the nurse practitioner’s educational
preparation or for which clinical competency has been established and maintained.
5) The drug or device ordered is appropriate to the condition being treated.
6) Patient education is given regarding the drug or device.
7) The name, title, and furnishing number of the nurse practitioner is written on the
transmittal order.
8) The Statement of Approval and Agreement signed by the nurse practitioners will act as
the record of nurse practitioners authorized to furnish.
9) No single physician will supervise more than four furnishing nurse practitioners at any
one time.
10) A physician must be available at all times in person, electronically or by telephone.
11) All other applicable Standardized Procedures in this document are followed during health
care management.
12) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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ORDERING SCHEDULED CONTROLLED SUBSTANCES

POLICY
The nurse practitioner is authorized to order scheduled controlled substances per the following
protocols:

PROTOCOLS
General
1) The nurse practitioner follows the provisions of the Standardized Procedure for
Furnishing.
2) The nurse practitioner’s name, title, furnishing and DEA numbers are on a secure
transmittal order.
3) Relevant scheduled drug contracts, DEA requirements, and all State and Federal
regulations are adhered to.
4) A CURES report is run on each patient receiving a controlled substance.
5) Schedule III and II substances are ordered following the Patient Specific Protocol (i.e.
Medication Assisted Therapy (MAT) protocol, Buprenorphine Induction Protocol,
Alcohol Withdrawal (Mild-Moderate) Protocol)
6) All other applicable Standardized Procedures in this document are followed during health
care management.
7) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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MEDICATION MANAGEMENT

POLICY
The nurse practitioner is authorized to manage drugs and devices under the following protocols:

PROTOCOLS
1) The management of drugs or devices includes evaluating, initiating, altering,
discontinuing, furnishing and ordering of prescriptive and over-the-counter medications.
2) Medication evaluation includes assessment of:
• Other medications being taken.
• Prior medications used for current condition.
• Medication allergies and contraindications, including appropriate labs and exams.
• Cures report (Cures report run every 3 months per clinic policy)
4) The drug or device is appropriate to the condition being treated, and:
•
•

Accepted dosages per references.
Generic medications are ordered if appropriate.

5) A plan for follow-up and refills is written in the patient's chart.
6) The prescription must be written in patient's chart including name of drug, strength,
instructions and quantity, and signature of the nurse practitioner.

7) All other applicable Standardized Procedures in this document are followed during health
care management.

8) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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IV. DISPENSING MEDICATIONS
POLICY
The nurse practitioner may dispense pre-packaged prescription drugs and devices, including
Schedule II-V controlled substances under the following protocols:

PROTOCOLS
1) The drug or device utilizes required pharmacy containers and labeling.
2) All appropriate record keeping practices of the dispensary are performed.
3) All State and Federal policies on dispensing Controlled Substance must be followed.
4) All other applicable Standardized Procedures in this document are followed during health
care management.
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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COMPLIMENTARY SAMPLES

POLICY

The nurse practitioner is authorized to sign for the request and receipt of complimentary samples
of prescription drugs and devices under the following protocols:

VI. PROTOCOLS
1) The list of Authorized Pharmaceutical Samples for Nurse Practitioner Signature is kept in
a secured area in the Clinical Coordinator’s office.
2) Each written request shall contain the name and address of the supplier and the requester,
the name and quantity of the specific dangerous drug desired, the name of the nurse
practitioner receiving the samples, the date of receipt, and the name and quantity of the
dangerous drugs or devices provided. These records shall be preserved by the supplier.
3) A review of this process will be part of the review of all the Standardized Procedures.
4) All other applicable Standardized Procedures in this document are followed during health
care management.
5) All General Policies regarding Review, Approval, Setting, Education, Evaluation, Patient
Records, Supervision and Consultation in these Standardized Procedures are in force.
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VII. AUTHORIZATIONS

VIII. POLICY
The nurse practitioner is authorized, under the following protocols, to:
•
•
•

Assess Worker’s Compensation injuries and illnesses.
Certify Disability.
Manage Home Health and Personal Care Services.

IX. PROTOCOLS
1)

Workers’ Compensation. The Doctor’s First Report of Occupational Injury or Illness,
co-signed by the nurse practitioner, for a workers’ compensation claim can be for a
period of time off from work not to exceed three calendar days. The treating physician
is required to sign the report and to make any determination of any temporary disability.

2)

Certify Disability. The nurse practitioner has performed a physical exam and
collaborated with a physician and surgeon.

3)

Home Health and Personal Care Services. Approval, signing, modifying, or adding to a
plan of treatment or plan of care is after consultation with the treating physician and
surgeon.

4)

All other applicable Standardized Procedures in this document are followed during
health care management.

5)

All General Policies regarding Review, Approval, Setting, Education, Evaluation,
Patient Records, Supervision and Consultation in these Standardized Procedures are in
force.
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In House Protocols:
• Medication-based therapies for opioid use disorder protocols
• Substance use disorder detoxification protocols
Examples of References:
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Dynamed
UptoDate
Epocrates
Medscape
CDC
USPSTF
SAMHSA Publications
ASAM National Practice Guideline
Current Medical Diagnosis and Treatment, Lange Series.
Primary Practice Guidelines in Primary Care
American Academy of Family Physicians. aafp.org/online
National Heart, Lung and Blood Institute Guidelines. nhlbi.nih.gov/guidelines
Procedures for the Primary Care Provider
Ferri’s Best Test
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Appendix P: Provider Satisfaction Survey

Survey Monkey
Provider Satisfaction Survey MAT Group

1.

2.
3.
4.

Question Title
a)
1. What qualities do you think make a successful
MAT program? w
Question Title
a)
2. What qualities or characteristics do you feel have
made the MAT program at CoRR successful? w
Question Title
a)
3. What would you like to see improve or change in
regard to the MAT program at CoRR? w
Question Title
a)
4. Would you like to see the interdisciplinary MAT
Group on Tuesday and Wednesday continue at CoRR? w

Yes
No
Other (please specify)

DONE
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Appendix Q: MAT Group Benchmark Data

CoRR MAT Group Pilot Program Data

Patient ID by DOB

Age Range

Patient #

Gender

Age

Visits

Retention

11

F

22

3

1

September 1, 1996

10

M

23

8

1

September 23, 1992

24

F

27

5

1

July 11, 1992

21

F

27

4

1

May 9, 1992

13

M

27

6

1

December 31, 1991

29

M

27

4

1

August 14, 1991

25

M

28

3

1

July 19, 1991

5

F

28

2

1

December 11, 1990

1

M

28

2

1

November 15, 1990

19

M

28

4

1

September 7, 1990

12

M

29

2

1

June 27, 1990

6

M

29

7

1

33

F

29

6

1

July 13, 1989

4

M

30

5

1

March 10, 1989

34

F

30

5

1

March 6, 1989

31

M

30

2

1

November 13, 1988

9

M

30

4

1

June 16, 1988

3

F

31

2

1

January 5, 1988

14

M

31

5

1

April 30, 1987

2

F

32

3

1

April 30, 1987

35

F

32

2

1

December 29, 1986

20

F

32

8

1

April 8, 1986

8

M

33

3

1

August 6, 1984

18

F

35

3

1

December 26, 1982

30

M

36

2

1

January 28, 1982

7

F

37

12

1

16

M

37

5

1

December 17, 1980

28

M

38

7

1

February 24, 1979

32

F

40

3

1

September 15, 1977

17

M

42

5

1

August 15, 1997

Retention
By Age
(Headcount)

Retention
By Age
(%)

2

6%

21

60%

18-25 years

December 25, 1989

December 10, 1981

26-34 years

35-55 years
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January 25, 1977

27

M

42

3

1

December 28, 1972

15

M

46

4

1

February 3, 1969

22

M

50

8

1

November 18, 1963

23

M

55

6

1

11

31%

26

M

69

6

1

1

3%

35*

100%

December 10, 1949

55 years +

TOT

MAT Retention Rate (%)
N = 47
Total Patients
R = 35*
Repeats (2<)
Retention Rate
74%
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Appendix R: Review of the Evidence
Citation
Conceptual Design/Method
Framework
Cicero, T.J., Ellis,
M.S., Surratt, H.L.
Kurtz, S.P. (2014).
The changing face of
heroin use in the
united states a
retrospective analysis
of the past 50 years.
Journal of American
Medical Association
Psychiatry,7(17),
821-826. doi:
10.1001/jamapsych
Iatry.2014.366

N/A

Retrospective
analysis,
utilizing a
mixed-method
approach

Sample/
Setting
-ongoing
nationwide
Survey of Key
Informants’
Patients (SKIP)
Program study
data employing
structured, selfadministered
surveys to
obtain
retrospective
data on prior
drug use
patterns for
patients
enrolling in
substance abuse
treatment
programs
across the
United States
and who had a
primary
diagnosis
(DSM-IV) of
heroin
use/dependence

Variables
Studied and
their Definitions
-IV: patients with
a primary
diagnosis (DSMIV) of heroin
use/dependence
who were
enrolled in
substance abuse
treatment
programs in the
United States
-DV: past drug
use patterns,
population
demographics
and current
residential
location
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Measurement

Findings

-population
demographics
and current
residential
location

-Researchers
Level III, B
found that the
demographics of
heroin users in the
United States has
changed from that
of a minority and
inner-city
problem, to one
that has a larger
geographic impact
and is now
composed of
mostly white men
and women (late
20’s) that reside
outside large
urban locations

-crosstabulations to
determine
prevalence rates
in terms of the
decade of when
the participant
first abused
opioids for: 1st
opioid used (i.e.
prescription
opioid or
heroin), sex,
race/ethnicity
and age at first
use

-The research
indicated that
many heroin users
had previously
used prescription
opioids

Appraisal
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Fiellin, D.A.,
N/A
Pantalon, M.V.,
Chawarski, M.C.,
Moore, B.A., Sulivan,
L.E., O’Connor, P.G.,
& Schottenfeld, R.S.
(2006). Counseling
plus buprenorphinenaloxone maintenance
therapy for opioid
dependence. The New
England Journal of
Medicine, 355, 365374. DOI: 10.1056/
NEJMoa055255

24-week
randomized,
controlled
clinical trial

-data collected
from
unstructured
qualitative
interviews with
a portion of the
patients who
participated in
the structured
interview
166 patients
who met
criteria for
opioid
dependence and
for opioidagonist
medication
treatment and
were assigned
to one of three
treatments:
-standard
medical
management
-either onceweekly or
thrice-weekly
medication
dispensing
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IV: one of three
treatments-standard medical
management,
either onceweekly or thrice
weekly
medication
dispensing or
enhanced
medical
management and
thrice-weekly
medication
dispensing
DV: frequency of
self-reported
drug use and
urinalysis testing

Primary
outcome
measures:
-Self reported
frequency of
illicit opioid use
-percentage of
opioid-negative
urine specimens
-self-reported
maximum
number of
consecutive
weeks of
abstinence from
illicit opioids
(confirmed
w/urinalysis)

-All three of the
treatments in the
study yielded a
decrease in the
mean selfreported
frequency of
opioid use
-No considerable
difference among
the three
treatment groups
or the treatments
over time
-Frequency of
illicit opioid use
was decreased
from baseline to
induction and the
lowest numbers
were seen during

Level II, C
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-enhanced
medical
management
and thriceweekly
medication
dispensing
Setting:
Primary Care
Center of YaleNew Haven
Hospital

Florence, C., Luo, F., Societal
Xu, L., & Zhou, C.
perspective
(2016). The economic
burden of prescription
opioid overdose,
abuse and dependence
in the united states,
2013. Medical Care,
54(10), 901-906.

-Incidence of
fatal prescription
overdose from
the National Vita
Statistics System

-United States
population
(fatal data)

-Representative
sample of
-Prevalence of
United States
abuse and
civilian nondependence from institutionalized
the National
population ages
Survey of Drug
12 and older
Use and Health
(nonfatal data)

Secondary
outcome
measures:

the maintenance
phase in all three
treatment groups

-amount of
patients
remaining in the
study

-Strategies to
improve
buprenorphinenaloxone
adherence
necessary

-# of days of the
study completed
-percentage of
cocaine-negative
urine samples
-patient
satisfaction
-use of health
and social
services
IV: patients with
opioid abuse and
dependence

DV:
-Loss of
productivity
defined as job
status and
household
responsibilities

Monetized strain
due to fatal
overdose and
misuse and
prescription
opioid
dependence

-The researchers
estimate that the
total economic
burden to equal
$78.5 billion
-One third of the
total amount is
due to the
increased health
care costs and cost
of substance
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-Cost data from
health care
claims data from
Truven Health
MarketScan
Research
databases
-Cost fatal cases
from WISQARS
(Web-based
injury Statistics
Query and
Reporting
System) cost
module
-Criminal justice
costs from the
Justice
Expenditure and
Employment
Extracts from the
Department of
Justice
-Estimates of
lost productivity
derived from a
previously
published study

100

-Cost
components
which included
health care,
substance abuse
treatment costs,
criminal justice
costs and lost
productivity
-Incidence of
prescription
opioid abuse and
dependence

abuse treatment
estimated to be
$28.9 billion
-One quarter of
the total cost is
absorbed by the
public sector (i.e.
health care,
substance abuse
treatment,
criminal justice
costs)
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Fudala, P.J., Bridge,
N/A
T.P., Herbert, S.,
Williford, W.O.,
Chiang, C.N., Jones,
K., Collins, J., Raisch,
D., Casadonte, P.,
Goldsmith, R.J., Ling,
W., Malkerneker, U.,
McNicholas, L.,
Renner, J., Stine, S.,
& Tusel, D.(2003).
Office-based
treatment of opiate
addiction with a
sublingual-tablet
formulation of
buprenorphine and
naloxone. New
England Journal of
Medicine, 349, 949958. DOI:
10.1056/NEJMoa022
164

Multicenter,
randomized,
placebocontrolled trial

-326 patients
with opioid
dependence
(ages 18-59)
who received
office-based
treatment
-Patients either
received
buprenorphine
(16mg)
w/naloxone
(4mg), only
buprenorphine
(16mg), or a
placebo daily
for four weeks
-“Safety data”
collected on
461 patients
w/opioid
dependence
who were
enrolled in an
open label
study of
buprenorphine
and naloxone
(daily doses=24
mg and 6mg)
and 11 patients
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IV: Patients with
opioid
dependence
receiving officebased treatment
w/ either
buprenorphine
(16mg)
w/naloxone
(4mg), only
buprenorphine
(16mg), or a
placebo daily for
four weeks
DV: reduction in
the use of opiates
and cravings for
opiates among
opiate addicted
patients

-percentage of
-Researchers
urine samples (-) concluded the
opiates
double-blind trial
prematurely as the
-patients selfbuprenorphine +
reported craving naloxone
for opiates
combination and
buprenorphine
were found to be
more effective
than the placebo.
-combination
buprenorphine
and naloxone and
buprenorphine
were found to be
safe and a decline
in the use of
opiates and
cravings was seen
in opiate
dependent patients
who received
these medications
in the office-based
setting
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Jones, E.B. (2018).
Medication-Assisted
opioid treatment
prescribers federally
qualified health
centers: capacity lags
in rural areas. The
Journal of Rural
Health, 34, 14-22.
doi: 10.1111/
jrh.12260

N/A

-Descriptive and
multivariable
analyses with the
weighted 2010
Assessment of
Behavioral
Health Services
survey data and
the 2010
Uniform Data
System
-Stata version 12
(Stat-aCorp LP,
College Station,
Texas) utilized
to conduct the
analysis

who were given
this medication
combination
during the trial
only
-2010 Uniform
Data System
(UDS)
administrative
data set
-2010
Assessment of
Behavioral
Health Services
in Federally
Qualified
Health Centers

102

-Independent
variables:
number of
patients served
annually, region,
urban status,
electronic health
record adoption,
whether the
health center
received funding
to serve homeless
individuals and
migrant and
seasonal
farmworkers, and
the percentage of
health center staff
that were
behavioral health
specialists (in the
models on the
availability of onsite
buprenorphine
and interest in
adding or
expanding the

-The availability
of on-site
treatment for
substance use
disorders in
2010

2010 Findings:
-47.6% of health
centers provided
on-site substance
use disorder
treatment

-The availability
of on-site mental
health treatment
services on-site
in 2010

-12.3% provided
buprenorphine
treatment for
opioids
-38.8% interested
in expanding
buprenorphine
availability
-Health centers
located in rural
areas had
decreased odds of
providing on-site
buprenorphine
treatment
(OR=0.49, 95%
CI: 0.26-0.94)
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availability of onsite medicationassisted treatment
w/buprenorphine)

Schwartz, R.P.,
Gryczynski, J.,
O’Grady, K.E.,
Sharfstein, J.M.,
Warren, G., Olsen,
Y., Mitchell, S.G., &
Jaffe, J.H. (2013).
Opioid agonist
treatments and heroin
overdose deaths in
baltimore, maryland,
1995-2009. American
Journal of Public
Health, 103(5), 917922.
doi:[10.2105/AJPH.
2012.301049]

N/A

Longitudinal
time series
analysis of
archival data
using linear
regression with
the Newey-West
method

-the insurance
status and type of
patient caseload
(uninsured,
Medicaid,
Medicare, other
public and
private)
-The number of IV:
heroin overdose the development
deaths from
of opioid agonist
1995-2009
(i.e. methadone
from the
and
Baltimore City buprenorphine)
Health
treatment
Department
DV: The number
-The number of of heroin
patients
overdose deaths
participating in from 1995-2009
Methadone
treatment for
opioid
dependence in
Baltimore City
from 19952009 from the
Maryland

-Rural health
centers had
decreased odds of
showing interest
in growing access
to buprenorphine
treatment (OR0.58, 95% CI:
0.35-0.97)

The correlation
between the
development of
methadone and
buprenorphine
treatment and
the incidence of
heroin overdose
deaths in
Baltimore
Maryland
between the
years of 19952009

-The researchers
found that
increased access
to opioid agonist
treatment (i.e.
methadone or
buprenorphine)
were correlated
with a decreased
number of heroin
overdose deaths.
-Schwartz et al.
recommend
enacting policies
that are congruent
with evidencebased medication
treatment of
opiate dependence
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Department of
Health’s
Alcohol and
Drug
Administration

Tsui, J.I., Evans, J.L.,
Lum, P.J., Hahn, J.A.,
& Page, K. (2014).
Association of opioid
agonist therapy with
lower incidence of
hepatitis c virus
infection in young
adult injection drug
users. Journal of the
American Medical
Association Internal
Medicine, 174(12),

N/A

Observational
cohort study
from 01/03/0008/21/13 with
quarterly
interviews and
blood sampling

-Estimated
number of
patients being
treated with
buprenorphinenaloxone
(Suboxone) or
buprenorphine
(Subutex) from
Wolters Kluwer
Pharma
Solutions
(WKPS)
Young adults
age <30 years
who were
injection drug
users and were
(-) anti-HCV
antibody and/or
HCV RNA in
San Francisco

as it may lead to a
reduction in the
amount of heroin
overdose deaths

IV: opioid
agonist therapy
(i.e.
buprenorphine or
methadone)
DV: lower
incidence of
HCV infection in
young adult IV
drug users

-HCV infection
documented
w/new + result
for HCV RNA
and/or HCV
antibodies

-Researchers
found that young
adult participants
with recent
maintenance
opioid agonist
therapy had an
associated lower
rate of HCV
infection.
-Maintenance
treatment with
opioid agonist
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1974-1981.
doi:10.1001/
jamainternmed.2014.
5416

Weiss, R.D., Potter,
J.S., Fiellin, D.A.,
Byrne, M., Connery,
H.S., Dickinson, W.,
Gardin, J., Griffin,
M.L., Gourevitch,
M.N., Haller, D.L.
Hasson, A.L., Huang,
Z., Jacobs, P.,
Kosinski, A.S.,
Lindblad, R.,
McCance-Katz, E.F.,
Provost, S.E., Selzer,
J., Somoza, E.C.,
Sonne, S.C., & Ling,
W. (2011).
Adjunctive
counseling during
brief and extended
buprenorphinenaloxone treatment
for prescription
opioid dependence a

N/A

Multi-site
randomized
clinical trial
utilizing a twophase adaptive
treatment
research design

-Study
participants
were age 18 or
older and
included 653
treatmentseeking
outpatients that
were dependent
on prescription
opioids
-10 treatment
sites in the
United States
that complied
w/DSM-IV
criteria for
prescription
opioid
dependence
from June
2006-July 2009

IV: 653 treatment
seeking
outpatients
dependent on
prescription
opioids at 10
U.S. sites
DV: minimal or
no opioid use at
phase 1 and/r
phase 2

Researchers
defined
“successful
outcome” in
phases 1 and 2 if
all determined
variables
demonstrated
minimal or no
opioid use on
urine drug
screen
confirmed
patient selfreports

therapy (i.e.
methadone or
buprenorphine)
for opioid use
disorders may
help to prevent the
contraction of
HCV infection in
this patient
population
-The researchers
Level I, B
concluded that
patients with
prescription
opioid
dependence were
“most likely” to
decrease opioid
use during
buprenorphinenaloxone
treatment
-Patients that were
stabilized on
buprenorphinenaloxone had
improved
outcomes versus
those patients who
were tapered off.
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2-phase randomized
controlled trial.
Archive of General
Psychiatry, 68(12),
1238-1246.
Doi:[10.1001/arch
genpsychiatry.2011.
121]

Weisner, C., Mertens, N/A
J., Parthasarathy, S.,
Moore, C., & Lu, Y.
(2001). Integrating
primary medical care
with addiction
treatment. Journal of
American Medical
Association, 286(14),
1715-1723. Retrieved
from
https://www.ncbi.nlm.
nih.gov/pmc/articles/
PMC3056510/

Randomized
controlled trial

Adult men and
women (n=592)
who were
admitted to a
large health
maintenance
organization
chemical
dependency
program in
Sacramento,
CA

IV: integrated
care (primary
health care +
addiction
treatment
program),
independent care
groups (separate
primary care and
substance abuse
treatment)
DV:

-Abstinence
outcomes
-treatment
utilization
-6 month costs
after
randomization

-Results of the
study found that if
patients were
tapered off
buprenorphinenaloxone
(including after
12 wks of
treatment) there
was a higher
possibility for
unsuccessful
outcome even if
patients were
undergoing
counseling with
medical
management
Researchers found Level I, B
that the patients
with substance
abuse-related
medical
conditions
benefited from the
integrated medical
and substance
abuse treatment
and this method
was cost
advantageous

THE DEVELOPMENT AND IMPLEMENTATION OF
Rosenblatt, R.A.,
N/A
Andrilla, C.H.A.,
Catlin, M., & Larson,
E.H. (2015).
Geographic and
specialty distribution
of US physicians
trained to treat opioid
use disorder. Annals
of Family Medicine,
13(1), 23-26.
doi:10.1370/afm.1735

Researchers
correlated
physicians that
were waivered to
prescribe
buprenorphine
on the July 2012
DEA Drug
Addiction
Treatment Act
(DATA) Waived
Physician List
with the
American
Medical
Association
Physician
Masterfile to
identify provider
age, specialty,
rural or urban
status and
geographical
location

Physicians
authorized to
prescribe
buprenorphine
in the United
States
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IV: Physicians in
the United States
who have
received a DEA
DATA waiver to
prescribe
buprenorphinenaloxone to treat
opioid use
disorder
DV: Access to
office-based
treatment of
opioid use
disorder (i.e.
buprenorphinenaloxone)

The amount of
physicians that
were waivered
to prescribe
buprenorphine
and
demographic
data such as
provider age,
specialty, rural
or urban status
and
geographical
location

-16% of
psychiatrists held
a DEA DATA
waiver (41.6% of
all MD’s
w/waivers) but
were primarily
located in urban
areas
-3% of primary
care providers had
received DEA
DATA waivers
which comprises
the biggest group
of MDs’ in rural
areas in the U.S.
-Most counties in
the U.S. did not
have access to
physicians’
w/waivers to
prescribe
buprenorphinenaloxone
-The authors
suggest increasing
access to officebased treatment of
opioid disorders
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especially in rural
areas in the U.S.
to address the
combat the
increase in opioid
use disorder and
unintentional
overdoses

